



Vaccines and Global Health: The Week in Review
01 November 2025 :: Issue 820
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director Center for Vaccine Ethics & Policy

david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.*

Support this knowledge-sharing service: *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

Contents [click to move among sections]

- :: [Milestones, Perspectives](#)
- :: [WHO](#)
- :: [U.S. Immunization and Public Health Governance/Policy/Funding](#)
- :: [Organization Announcements](#)
- :: [Journal Watch](#)
- :: [Pre-Print Servers](#)
- :: [Think Tanks](#)
- :: [Public Consultations/Call for Inputs/Call for Papers](#)

Milestones, Perspectives

.....
.....

Monitoring and reporting of essential immunization catch-up: implementation guidance

WHO - UNICEF

15 October 2025

Executive summary

The Big Catch-Up is a global initiative launched in April 2023 to close gaps in immunization caused by the reduction in immunization coverage during the COVID-19 pandemic, to restore global immunization levels and to strengthen immunization systems so that catch-up activities become an integral part of immunization programmes.

Countries are employing various approaches to catch up unvaccinated and under-vaccinated children. Such approaches include routine service delivery, periodic intensification of routine immunization (PIRI), and supplementary immunization activities (SIAs). However, there is a significant challenge because routine information systems, including vaccination recording and reporting tools, are often not yet adapted to capture catch-up vaccinations.

This document guides ministries of health, in-country immunization partners, and regional and global stakeholders in monitoring the Big Catch-Up and to employ catch-up as an integral part of routine immunization.

Catch-up strategies should be tailored to each country's needs. The first step is to adapt existing in-country tools such as tally sheets, home-based records and immunization registers to capture the age group to which each vaccine dose is given. Health workers should be trained to screen each child's age and vaccination status and to vaccinate according to a nationally available catch-up schedule. Large-scale catch-up activities should be accompanied by targeted field assessments, such as post-campaign coverage surveys or rapid convenience monitoring. More advanced evaluations can also be considered, including surveys and in-depth case studies. In addition, countries should collect behavioural and social driver data on vaccine uptake in order to understand enablers of – and barriers to – catch-up activities.

Suggested indicators at the country level include the availability of a catch-up policy and schedule, adapted data collection tools and the number of catch-up activities implemented.

Suggested indicators at the global level include: the availability of approved catch-up and recovery plans, policies, schedules, tools and activities; information systems for capturing delayed doses; appropriate budgeting; additional vaccines requested and received; delayed doses administered; and children reached.

Monitoring the Big Catch-Up is vital to close immunization gaps and prevent further disease outbreaks. It is also essential to learn from the initiative's success, and to ensure accountability between countries, in-country partners, and global stakeholders. During the Big Catch-Up and beyond, data systems should be strengthened to capture delayed doses, and catch-up monitoring should be integrated into all systems for monitoring routine vaccination coverage to ensure that no one is left behind.

.....
.....

Gates and Global Health

Editor's Note:

Last week, an open letter by Bill Gates and a *BMJ Global Health* article resulted in “Gates” becoming an anchor in global health policy dialog. The open letter, released in advance of COP 30, argues for a “pivot” in climate change strategy and investment putting “human welfare” [disease and poverty] at the center. The *BMJ Global Health* article analyzes Gates Foundation funding to WHO from 2000-2024, confirming BMGF as the second largest funder after the U.S. [as least historically] with the programs it funds clearly weighted towards infectious disease.

.....

Three tough truths about climate

A new way to look at the problem...What I want everyone at COP30 to know.

By Bill Gates, “published 5 days ago”

What to Know

- Climate change is serious, but we’ve made great progress. We need to keep backing the breakthroughs that will help the world reach zero emissions.
- But we can’t cut funding for health and development—programs that help people stay resilient in the face of climate change—to do it.
- **It’s time to put human welfare at the center of our climate strategies**, which includes reducing the Green Premium to zero and improving agriculture and health in poor countries.

...It’s not too late to adopt a different view and adjust our strategies for dealing with climate change. Next month’s global climate summit in Brazil, known as COP30, is an excellent place to begin, especially because the summit’s Brazilian leadership is putting climate adaptation and human development high on the agenda.

This is a chance to refocus on the metric that should count even more than emissions and temperature change: improving lives. **Our chief goal should be to prevent suffering, particularly for those in the toughest conditions who live in the world’s poorest countries.**

Although climate change will hurt poor people more than anyone else, for the vast majority of them it will not be the only or even the biggest threat to their lives and welfare. **The biggest problems are poverty and disease, just as they always have been.** Understanding this will let us focus our limited resources on interventions that will have the greatest impact for the most vulnerable people...

...COP30 is taking place at a time when it’s especially important to get the most value out of every dollar spent on helping the poorest. The pool of money available to help them—which was already less than 1 percent of rich countries’ budgets at its highest level—is shrinking as rich countries cut their aid budgets and low-income countries are burdened by debt. **Even proven efforts like providing lifesaving vaccines for all the world’s children are not being fully funded. Gavi (the vaccine-buying fund) will have 25 percent less money for the next five years compared to the past five years.** We have to think rigorously and numerically about how to put the time and money we do have to the best use.

So I urge everyone at COP30 to ask: How do we make sure aid spending is delivering the greatest possible impact for the most vulnerable people? Is the money designated for climate being spent on the right things?

I believe the answer is no...

→ TRUTH #1 ←

Climate change is a serious problem, but it will not be the end of civilization.

Even if the world takes only moderate action to curb climate change, the current consensus is that by 2100 the Earth's average temperature will probably be between 2°C and 3°C higher than it was in 1850...

→ TRUTH #2 ←

Temperature is not the best way to measure our progress on climate.

The global temperature doesn't tell us anything about the quality of people's lives. If droughts kill your crops, can you still afford food? When there's an extreme heat wave, can you go somewhere with air conditioning? When a flood causes a disease outbreak, can the local health clinic treat everyone who's sick? Quality of life may seem like a vague concept, but it's not. One useful tool for measuring it is the United Nations' [Human Development Index](#), which provides a snapshot of how people in a country are faring—from 0 to 1, with higher numbers meaning better outcomes.

→ TRUTH #3 ←

Health and prosperity are the best defense against climate change.

...I'm not saying we should ignore temperature-related deaths because diseases are a bigger problem. In fact, temperature-related deaths are one of the reasons why cheap clean energy is so important—it will make heating and air conditioning more affordable everywhere.

What I am saying is that we should deal with disease and extreme weather in proportion to the suffering they cause, and that we should go after the underlying conditions that leave people vulnerable to them. While we need to limit the number of extremely hot and cold days, we also need to make sure that fewer people live in poverty and poor health so that extreme weather isn't such a threat to them.

Artificial intelligence has already begun to help do that. Today, for example, AI-powered devices make it possible for health workers to provide ultrasound exams for pregnant women in low-income settings—a breakthrough that means many more women will get the treatment they need to survive childbirth and deliver a healthy baby. **AI is also helping researchers develop new vaccines and treatments faster, adding to the long list of affordable lifesaving tools that are already available, including vaccines, biofortified foods, bed nets, and treatments for diseases like AIDS, malaria, and tuberculosis...**

So I urge that community, at COP30 and beyond, to make a strategic pivot: prioritize the things that have the greatest impact on human welfare. It's the best way to ensure that everyone gets a chance to live a healthy and productive life no matter where they're born, and no matter what kind of climate they're born into.

.....

BMJ Global Health.

2025;10:e015343. <https://doi.org/10.1136/bmjgh-2024-01534>

Original research

Who's leading WHO? A quantitative analysis of the Bill and Melinda Gates Foundation's grants to WHO, 2000-2024

Kennedy J, Thakrar R.

Abstract

Introduction

The Bill and Melinda Gates Foundation (BMGF) has been the World Health Organization's (WHO) second biggest source of funding in recent years, contributing 9.5% of WHO's revenues between 2010 and 2023 through voluntary contributions. It is widely assumed that BMGF's financial power allows it to exert considerable influence over WHO. However, very little empirical research has been undertaken into the BMGF-WHO relationship. Our study investigates how the money that BMGF gives to WHO is spent.

Methods

We constructed a dataset of BMGF grants to WHO for the period 2000–2024 by extracting and coding data retrieved from BMGF's website. The dataset was analysed to examine the number and value of grants, and the diseases or health issues and activities that were funded.

Results

BMGF made 640 grants worth \$5.5 billion to WHO between 2000 and 2024. This is 6.4% of all BMGF's grants by value in the period. Grants worth \$4.5 billion focused on infectious diseases. This amounts to 82.6% of all BMGF contributions to WHO by value. Of these, \$3.2 billion (58.9%) went to polio. \$2.9 billion – 53.3% of the money BMGF disbursed to WHO – funded vaccine programmes and projects. Relatively little BMGF funding went to non-communicable diseases, strengthening health systems, and broader determinants of health, despite their importance to WHO strategy and global health more generally.

Conclusion

WHO's reliance on earmarked voluntary contributions means that global health challenges favoured by major donors' are well funded while other issues receive insufficient funding. As one of WHO's biggest donors, BMGF contributes to this problem by pursuing its narrow approach to global public health – one that focuses on technical solutions to infectious diseases – through WHO.

What is already known on this topic

:: The Bill and Melinda Gates Foundation (BMGF) is the World Health Organization's (WHO) second biggest source of funding, contributing 9.5% of WHO's revenues between 2010 and 2023.

What this study adds

:: BMGF made 640 grants worth \$5.5 billion to WHO between 2000 and 2024. This amounts to 6.4% of all money disbursed by BMGF in the period.

:: \$4.5 billion or 82.6% of all BMGF contributions to WHO went to infectious diseases, of which \$3.2 billion (58.9%) went to polio – despite polio accounting for an insignificant proportion of the global burden of disease.


:: A small proportion of the money BMGF gave to WHO goes to strengthening health systems, non-communicable diseases, and broader determinants of health, despite their importance to WHO's strategy and global health more generally.

How this study might affect research, practice or policy

:: Our study emphasises an important point for global health practice and policy: without flexible and sustainable sources of funding WHO will struggle to achieve its strategic aims.

Figure 1

Allocation of BMGF grants to WHO by disease or health issue, 2000-2024 Source: <https://www.gatesfoundation.org/about/committed-grants> Notes: * refers to infectious diseases. 'General health' is a broad classification that covers grants that do not fit into other categories. See text for examples. The total of all grants is \$5.5 billion.



Conclusion

What should WHO do?

WHO is an exceptional organisation in global health. As the UN's specialised agency for health, WHO has a unique legitimacy. Its constitutional commitment to a broad, rights-based conceptualisation of health provides a valuable alternative to less political approaches. For several decades, WHO's independence has been diminished by a perpetual funding crisis. Assessed contributions from member states are nowhere near the level needed to fund its strategic priorities, so WHO must rely on earmarked voluntary contributions from donors. Consequently, activities and areas that donors favour receive more resources than are required while those they are not interested in do not get enough.

As WHO's second biggest funder, BMGF contributes to the suboptimal distribution of resources in WHO's budget. The foundation's emphasis on using vaccines to tackle infectious diseases means that it overlooks some major global health challenges that are of strategic importance to WHO. When other funders are willing to fund these – as with health systems strengthening – this is not a problem. But when neither BMGF nor other major voluntary donors give much money to an issue, it creates a 'pocket of poverty' in WHO's budget. This is the case with non-communicable diseases.

It is easy to blame major donors like BMGF for undermining WHO's independence and pursuing its agenda through WHO. Recent calls to decolonise global health have highlighted the character of private foundations like BMGF and their outsized impact on the sector in general, as well as the way that they influence WHO.^{[14](#)}

We should not, however, lose sight of the fact that it is the member states' failure to increase assessed contributions in line with WHO's needs over the last four decades that has created a situation in which the organisation is forced to rely on voluntary contributions from donors like BMGF. WHO has asked for

more flexible and sustainable funding, warning that without fundamental changes to the way it is financed, it will be unable to achieve its strategic aims. If the member states continue to ignore these exhortations, then WHO will remain vulnerable to the influence of external donors and will struggle to address the full spectrum of contemporary global health challenges.

.....
.....

Urban Health

[WHO calls for a new era of strategic urban health action with global guide to unlock healthy, prosperous and resilient societies](#)

31 October 2025 *News release*

On World Cities Day, the World Health Organization (WHO) calls on national and city leaders to transform urban areas into engines of health, equity and sustainability.

More than 4.4 billion people, over half of humanity, now live in urban areas, a figure projected to rise to nearly 70% by 2050. In cities health, inequality, environment and economy intersect in powerful and dramatic ways, creating both complex risks and unique opportunities for progress. While health challenges loom in all urban settings, the worst health outcomes are often concentrated in slums and informal settlements, with residents enduring unsafe housing, inadequate sanitation, food insecurity, and rising exposure to floods and heat. Today, 1.1 billion people live in these conditions, a number expected to triple by 2050.

With the new guide for decision-makers launched today "Taking a strategic approach to urban health" WHO provides concrete ideas to usher in a new era of urban health action. The Guide responds to the growing demand for integrated solutions that address health challenges and promote health more broadly in urban settings. It is the first comprehensive framework of its kind to help governments plan urban health strategically, integrating evidence into policy and practice.

"This is a moment for decision-makers at every level to act together," said Jeremy Farrar, Assistant Director General, for Health Promotion, Disease Prevention and Care, WHO. **"The guide gives national and municipal leaders, planners, partners and communities a framework to work together, across sectors and scales, to build fairer, healthier, and more resilient futures."**

Health risks and inequities are seen in all urban areas: a study of 363 cities in nine Latin American countries found life expectancy gaps of up to 14 years for men and 8 years for women between the healthiest and least healthy cities. Urban residents everywhere face multiple, overlapping risks – from air pollution and unsafe transport to poor housing, noise and climate hazards. Air pollution alone kills around 7 million people annually, and nearly every city dweller breathes air that fails to meet WHO air quality guideline values. Dense populations heighten risks for infectious outbreaks such as COVID-19 and dengue and limited access to green spaces increases the risk for noncommunicable diseases.

Urban environments have now become the dominant day-to-day influence on human health – while also driving global challenges such as climate change, resource scarcity, and growing inequality. This makes them not only the front line for today's health challenges, but the greatest hope for transformative change...

The Guide emphasizes that health is not the responsibility of one sector alone, nor limited to the decisions of city officials. From clean air and safe housing to active mobility and digital access, to broader financing and regulatory action, decisions made every day by urban authorities across multiple sectors and scales affect the health of billions. Taking strategic action means aligning these choices to

build healthier and fairer futures, where urban systems work together to advance equity, sustainability and resilience.

"Taking a Strategic Approach to Urban Health" outlines practical steps for governments to:

- understand the complexity of urban systems and how they shape health and equity;
- identify entry points for action, recognizing opportunities to build urban health across policy and practice agendas in other sectors and issues;
- strengthen the means of implementation for urban health, including governance, financing, data, analytics, innovation, capacity-strengthening, partnerships and participation; and
- develop comprehensive urban health strategies at both national and city levels.

WHO calls on municipal and national leaders to adopt a more strategic approach to urban health, recognizing the crucial role that local and national governments play in creating coherent health action that aligns with other societal goals, and making urban areas not only more livable, but more just and sustainable.

Alongside the Guide, WHO is launching the first three modules of an Urban Health E-learning course, hosted by the WHO Academy, to strengthen capacities for collaborative work in urban contexts.

.....

Editor's Note:

We note that in the 170 pages of the [Taking a strategic approach to urban health](#) report, the term "immunization" does not appear, and the terms "vaccine" or "vaccination" appear in one sentence:

...Promising interventions lose effectiveness over time, even with increasing investment. For example, behaviour change campaigns, such as those around diet or exercise, can produce strong initial results, but become less effective as their novelty wears off; the elimination of diseases through vaccination can lead to vaccine hesitancy in individuals and populations that no longer perceive a threat... [p.63]

.....

.....

Mpox

[Multi-country outbreak of mpox, External situation report #59 - 30 October 2025](#)

WHO - *Emergency situation reports*

30 October 2025 PDF: https://cdn.who.int/media/docs/default-source/documents/emergencies/multi-country-outbreak-of-mpox--external-situation-report--59.pdf?sfvrsn=8d4ffb26_3&download=true

Overview

This is the 59th situation report for the multi-country outbreak of mpox, which provides details on the global epidemiological situation for mpox, including an update on the epidemiological situation with data on the global situation as of 30 September 2025, in Africa as of 19 October and the operational response updates as of 24 October 2025.

[Excerpt]

5. Access to and delivery of countermeasures

Access and Allocation Mechanism (AAM) and mpox vaccine delivery

Vaccines

- **WHO continues to provide guidance and technical support** to countries on mpox vaccination strategies, with a focus on geographic areas with new cases, and in those, people at risk of exposure based on local epidemiology. In addition, with the aim of optimizing the limited vaccine

supply due to funding constraints, WHO is supporting countries on planning for the use of dose-sparing options (single dose or intradermal fractional dosing) of MVA-BN vaccine.

- **All MVA-BN vaccine doses allocated in the first six allocation rounds have been delivered, and an additional 150 000 doses have been allocated in a seventh round**, to Kenya, Liberia and Uganda.
- **Mpox vaccination activities have started in 13 countries** with MVA-BN vaccine (Angola, Côte d'Ivoire, the Central African Republic, Democratic Republic of the Congo, Ghana, Kenya, Liberia, Malawi, Nigeria, Rwanda, Sierra Leone, South Africa and Uganda). Most of them are implementing a single-dose strategy targeting population groups at high risk of exposure. More than 1.16 million MVA-BN vaccine doses have been administered in these 13 countries.
- **More than 684 000 doses of MVA-BN and 118 000 doses of LC16 have been administered in the Democratic Republic of the Congo**, which accounts for more than 61% of people vaccinated in African countries. Other countries that recently reported mpox are developing national mpox vaccination plans and are encouraged to consider dose-sparing options of the MVA-BN vaccine. Additional doses have been donated and procured; funding is still needed to secure additional vaccine supply from manufacturers.
- **The AAM partners continue to work together** to support access to mpox vaccines and secure operational funds for implementation of national mpox vaccination plans.

.....
.....

Cholera

[Multi-country outbreak of cholera, external situation report #31 -29 October 2025](#)

WHO - Emergency situation reports

29 October 2025

Overview

From 1 January to 28 September 2025, a cumulative total of 518 324 cholera cases and 6508 deaths were reported from 32 countries across five WHO regions, with the Eastern Mediterranean Region recording the highest numbers, followed by the African Region, the South-East Asia Region, the Region of the Americas, and the Western Pacific Region. No cases were reported from the European Region during this period.

In September 2025, a total of 45 765 new cholera and acute watery diarrhoea cases were reported from 21 countries across four WHO regions, showing a 27% decrease from August. The period also saw 601 cholera-related deaths globally, a 37% decrease from the previous month.

The preliminary number of deaths reported in 2025, as of 28 September, has already surpassed the 2024 total of 6028, which was itself a 50% increase on 2023.

In September 2025, the average stockpile of Oral Cholera Vaccine (OCV) was 5.2 million doses, exceeding the emergency threshold of 5 million doses during two weeks of the reporting period. This is the first time in three months that the average stockpile exceeded this threshold.

.....
.....

Polio – PHEIC

[Polio this week](#) [29 October 2025]

Headlines

:: World Polio Day 2025 – Global Voices Unite for a Polio-free Future

"In a world that often feels divided, the fight against polio reminds us what is possible when humanity stands together." Dr Tedros Adhanom Ghebreyesus, WHO Director-General

Across every region, partners and advocates came together on World Polio Day 2025 to celebrate progress, renew commitment, and call for the final push to end polio for good. From [Bill Gates](#) and WHO Director-General [Dr Tedros](#) to frontline health workers and survivors like [Ramesh Ferris](#), powerful stories reminded the world how far we've come—and how close we are to achieving a polio-free future. Events from [Roosevelt Island](#) to [UNICEF HQ](#) and beyond underscored a shared determination to finish the job, as governments, civil society, and [Rotarians](#) from around the world reaffirmed their support.

Summary of new polioviruses this week:

- :: Pakistan: one WPV1 case and 12 WPV1-positive environmental samples
- :: Angola: two cVDPV2 cases and one cVDPV2-positive environmental sample
- :: Chad: one cVDPV2-positive environmental sample
- :: Nigeria: seven cVDPV2 cases and one cVDPV2-positive environmental sample
- :: Papua New Guinea: one cVDPV2 case and five cVDPV2-positive environmental samples
- :: Somalia: one cVDPV2-positive environmental sample

.....

Polio transition strategic framework: Global Vision to use polio investments to build strong, resilient and equitable health systems

WHO - Global Strategy

26 October 2025 [Download \(2.8 MB\)](#)

Overview

The Global Vision to use polio investments to build strong, resilient and equitable health systems is the umbrella for the Polio transition strategic framework, which updates the Strategic Action Plan on Polio Transition (2018-2023). It builds on stakeholder feedback to set the strategic direction to sustain the polio investments – the tools, knowledge and infrastructure built to eradicate polio over the past decades – and use this legacy to keep the world polio-free and build strong, resilient and equitable health systems.

[Excerpt]

Introduction

This document presents the Global Vision to use polio investments to build strong, resilient and equitable health systems, a crucial step towards sustaining the gains made in polio eradication, while employing this legacy to promote, provide and protect the health and well-being of communities on the way to achieving the Sustainable Development Goals (SDGs).

The Global Vision aims to mobilize stakeholders – national governments, WHO, UNICEF, civil society organizations, donors, funding agencies and other partners – to take advantage of the unique opportunity to make a long lasting contribution to public health, through renewed commitment and enhanced collaboration. The Global Vision is part of a flexible strategic framework, alongside regional strategic plans (RSPs), country action plans, and a monitoring and evaluation framework. It sets the overall strategic direction and is the umbrella for the strategic framework. The RSPs and country action plans will define implementation strategies tailored to specific regional and country contexts. The Polio Transition Monitoring and Evaluation (M&E) Framework will ensure progress tracking, enhance accountability and enable timely course corrections.

The strategic framework builds on the lessons learned from the Strategic Action Plan on Polio Transition (2018–2023), aiming to address the latter's gaps and shortcomings. Most importantly, it offers a flexible approach, taking into account the specific context of each country.

Instead of setting a fixed timeline, the strategic framework proposes milestones that each country will strive to achieve at its own pace, facilitated by alignment and collaboration among stakeholders.

The Global Vision’s strategic outcomes are universal. Reaching and sustaining polio eradication is a global public health good, and every country needs to safeguard a set of essential functions until and beyond eradication. The operational outcomes, on the other hand, are primarily applicable to countries that rely on GPEI support and to places action is most needed. They are intended to chart a path towards a well-planned transition of functions to national health systems...

Fig. 2. Polio transition strategic framework: global vision.





Fig. 3. Polio eradication, transition and post-certification phases and trajectory.



.....

Contents [click to move among sections]

- :: [Milestones, Perspectives](#)
- :: [WHO](#)
- :: [U.S. Immunization and Public Health Governance/Policy/Funding](#)
- :: [Organization Announcements](#)
- :: [Journal Watch](#)
- :: [Pre-Print Servers](#)
- :: [Think Tanks](#)
- :: [Public Consultations/Call for Inputs/Call for Papers](#)

.....

WHO & Regional Offices [01 Nov 2025]

<https://www.who.int/news>

Selected News/Announcements/Statements

31 October 2025 *News release*

[WHO calls for a new era of strategic urban health action with global guide to unlock healthy, prosperous and resilient societies](#)

31 October 2025 *Departmental update*

[WHO brings together Member States to strengthen quality and safety of traditional, complementary and integrative medicine products](#)

30 October 2025 *Departmental update*

Bangladesh: from outbreak to preparedness: protecting Rohingya communities against cholera

29 October 2025 *News release*

WHO condemns killings of patients and civilians amid escalating violence in El Fasher, Sudan

29 October 2025 *Departmental update*

16th Annual Meeting of the WHO International Regulatory Cooperation for Herbal Medicines (IRCH)

29 October 2025 *News release*

Climate inaction is claiming millions of lives every year, warns new Lancet Countdown report

:::::::

WHO Vaccines and Immunization [IVB]

https://www.who.int/health-topics/vaccines-and-immunization#tab=tab_1

Updates

15 October 2025

Monitoring and reporting of essential immunization catch-up: implementation guidance

:::::::

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region AFRO

No new digest content identified.

WHO Region of the Americas PAHO

:: 31 Oct 2025

PAHO presents regional agreement to eliminate syphilis, a disease that affects 3.4 million people in the Americas

Washington, D.C., October 31, 2025 (PAHO) – Cases of adult syphilis increased by 26% between 2020 and 2022 in the Americas—reaching 3.4 million—and by another 10% between 2022 and 2024, according to the Pan American Health Organization (PAHO). To reverse this trend, PAHO has released a set of 15 key recommendations aimed at eliminating syphilis and...

:: 31 Oct 2025

PAHO supports Haiti's health response following heavy rains linked to Hurricane Melissa

Port-au-Prince, Haiti, October 31, 2025 (PAHO/WHO)— The Pan American Health Organization/World Health Organization (PAHO/WHO) is supporting the Ministry of Public Health and Population (MSPP) in responding to the severe flooding caused by heavy rains associated with Hurricane Melissa, which have resulted in loss of life and extensive damage...

:: 31 Oct 2025

PAHO, HCC and GHAI Convene Stakeholders to Address the Commercial Determinants of NCDs in Caribbean SIDS

Bridgetown, Barbados, 31 October 2025. From October 15-17, 2025, the Healthy Caribbean Coalition (HCC) with the support of the Pan American Health Organization (PAHO) and the Global Health Advocacy Incubator (GHAI) hosted a regional meeting entitled: Addressing the Commercial Determinants of NCDs in Caribbean SIDS: Protecting NCD policymaking...

:: 29 Oct 2025

[Digital Health: Cycle on Artificial Intelligence in Public Health now available on YouTube](#)

The Information Systems and Digital Health Unit (IS/EIH) announces the publication of the Webinar, Masterclass, and Meet the Expert sessions on PAHO's YouTube channel. Registration is also open for the next live session on November 6. Washington D.C., October 30, 2025 (PAHO) – The Information Systems and Digital Health Unit (IS/EIH) announced that...

:: 29 Oct 2025

[PAHO sends emergency medical supplies to countries affected by Hurricane Melissa](#)

The Organization delivers more than 2.6 tons of supplies to Cuba and has 5.5 additional tons ready for Jamaica as soon as the country's airport reopens Havana/Washington D.C., October 29, 2025 (PAHO) – The Pan American Health Organization (PAHO) delivered more than 2.6 tons of essential medical supplies to Cuban health authorities to support...

WHO South-East Asia Region SEARO

No new digest content identified.

WHO European Region EURO

:: 30 October 2025 *News release*

[Governments across Europe and Central Asia adopt new WHO strategy to give every child a healthy start in life](#)

:: 30 October 2025 *Media release*

[The WHO European Region adopts bold new 5-year vision for health and resilience](#)

WHO Eastern Mediterranean Region EMRO

[WHO trains 140 000 health workers ahead of Pakistan's drive to protect 35 million children from measles and rubella](#)

30 October 2025

[WHO condemns killings of patients and civilians amid escalating violence in El Fasher, Sudan](#)

29 October 2025

[Immunization: progress and challenges in the Eastern Mediterranean Region](#)

27 October 2025

WHO Western Pacific Region

:: 30 October 2025 *Joint News Release*

[KOICA-funded upgrades strengthen Fiji CDC lab capacity](#)

.....

WHO - Emergency situation reports

Latest WHO official reports for emergency situations. Latest WHO official reports for emergency situations.

30 October 2025

[Multi-country outbreak of mpox, External situation report #59 - 30 October 2025](#)

29 October 2025

[Multi-country outbreak of cholera, external situation report #31 -29 October 2025](#)

.....

Disease Outbreak News (DONs)

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

No new digest content identified.

::::::

Weekly Epidemiological Record

Vol. 100, No. 43, pp. 483–498 24 October 2025

<https://www.who.int/publications/journals/weekly-epidemiological-record>

:: Genetic and antigenic characteristics of zoonotic influenza A viruses and development of candidate vaccine viruses for pandemic preparedness

::::::

New WHO Publications

<https://www.who.int/publications>

Selected

30 October 2025

[Digital transformation handbook for health product catalogue](#)

30 October 2025

[Competency and outcomes framework for adolescent health and well-being](#)

30 October 2025

[Global traditional medicine strategy 2025-2034](#)

29 October 2025

[The role of the health sector in supporting parents and caregivers to meet their parenting potential](#)

27 October 2025

[Risk evaluation of circulating Middle East respiratory syndrome coronavirus \(MERS-CoV\) clades and lineages](#)

27 October 2025

[Taking a strategic approach to urban health: a guide for decision-makers](#)

27 October 2025

[Dengue case management for primary health care and home-based care: Booklet for health professionals...](#)

26 October 2025

[Polio transition strategic framework: Global Vision to use polio investments to build strong, resilient...](#)

::::::

::::::

::::::

Africa

Africa CDC [01 Nov 2025]

<https://africacdc.org/>

Press Releases, Statements [Selected]

Press Releases

[Africa CDC Mobilises Emergency Public-Health Response After Hospital Attack in Sudan](#)

1 November 2025

Press Releases

[Africa CDC Strengthens Mpox Response through Additional Vaccine Support from Bavarian Nordic](#)

28 October 2025

Addis Ababa, Ethiopia | October 28, 2025 – Africa CDC has received an additional donation of 110,000 doses of mpox vaccines from Bavarian Nordic to support the ongoing response to the mpox outbreak across the continent...

Press Releases

[4th International Conference on Public Health in Africa \(CPHIA\) Closes with Launch of 'The Durban Promise'](#)

27 October 2025, Durban, South Africa —The 4th International Conference on Public Health in Africa (CPHIA 2025) closed on 25 October with the launch of The Durban Promise. This outcome document synthesises conference recommendations to define Africa's roadmap toward self-reliance, sustainability, and leadership in global health. The document will inform upcoming policy discussions, including the G20 meeting in South Africa, aimed at accelerating Africa's progress on health equity, solidarity, and universal health coverage.

The Durban Promise includes seven continental commitments:

1. Mobilise Africa's Wealth and Innovation for Health Sovereignty
2. Strengthen Governance and Accountability
3. Reinvest in PHC and Community Systems
4. Foster Regional Solidarity and Market Efficiency
5. Build Integrated, Climate-Resilient and Pandemic-Ready One Health Systems
6. Reframe Health as a Strategic Investment
7. Transform This Moment into Africa's Leadership Era

"This moment enables South Africa to carry the voice of the continent into the G20 deliberations—championing fair global health financing, resilient systems, and recognition of Africa as a strategic contributor, not a passive recipient," said Professor Olive Shisana, CPHIA 2025 Co-chair, in her remarks during the closing ceremony.

CPHIA 2025 brought together nearly 20,000 participants from over 72 countries — both online and in Durban — from across governments, academia, and civil society. Held under the theme "*Moving Toward Self-Reliance to Achieve Universal Health Coverage and Health Security*," the conference was hosted by the Africa Centres for Disease Control and Prevention (Africa CDC), and co-organised with the Government of South Africa and AfricaBio's BIO Africa Convention...

.....
.....

China – CDC+

<http://www.chinacdc.cn/en/>

National Health Commission of the People's Republic of China [01 Nov 2025]

<http://en.nhc.gov.cn/>

News

[China aims to raise average life expectancy to around 80 years in 5 years](#)

Updated: 2025-10-28 | Xinhua

BEIJING -- China aims to increase the average life expectancy of its people to around 80 years through efforts planned for a five-year period from 2026 to 2030, announced the country's top health official on Friday.

By the end of 2024, the average life expectancy of the Chinese people had reached 79 years — an extraordinary achievement among developing countries, said Lei Haichao, head of the National Health Commission.

According to Lei, China has established the world's largest health service system, disease prevention and control system, and medical insurance system over the past five years, marking remarkable progress in the country's healthcare and population development....

National Medical Products Administration – PRC [01 Nov 2025]

<http://english.nmpa.gov.cn/>

News

No new digest content identified.

China CDC

CCDC Weekly Reports: Current Volume (7)

2025-10-31 / No. 44 WORLD FLU DAY ISSUE

[PDF of this issue](#)

- Commentary: Preparing for the Next Influenza Pandemic: Vaccine Progress, Challenges, and Prospects

...The substantial impacts of influenza pandemics on global public health, economies, and societies underscore the critical importance of effective preparedness and response strategies to reduce pandemic severity, save lives, and minimize socio-economic disruptions. Vaccines represent the most effective intervention for preventing influenza and its complications. However, developing vaccines for pandemic influenza viruses presents significant challenges. The virus mutates rapidly, and predicting which strain will trigger the next pandemic remains difficult. Here we address the progress, challenges, and prospects for vaccine development in preparation for the next influenza pandemic....

- Preplanned Studies: Epidemiological Assessment and Optimization of School-Based Influenza Vaccination — Shenzhen City, Guangdong Province, China, 2023–2024
- Preplanned Studies: Phylogenetic and Molecular Characteristics of An H3N8 Avian Influenza Virus Detected in Wild Birds — Beijing, China, September 2024
- Methods and Applications: Developing Machine Learning Prediction Model for Daily Influenza Reported Cases Using Multichannel Surveillance Data — A City, Hubei Province, China, 2023–2025
- Outbreak Reports: Epidemiological and Genetic Characterization of Three H9N2 Viruses Causing Human Infections — Changsha City, Hunan Province, China, April 2025

.....

.....

Europe

European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

News/Updates/Reports/Publications [Selected]

Surveillance and monitoring

Communicable disease threats report, 25 - 31 October 2025, week 44

31 Oct 2025

This issue of the *ECDC Communicable Disease Threats Report (CDTR)* covers the period 25 October – 1 November 2025, and includes updates on respiratory virus epidemiology in the EU/EEA, chikungunya virus disease, West Nile virus, dengue, Ebola Virus Disease, Rift Valley Fever, and mpox.

European Medicines Agency [EMA]

<https://www.ema.europa.eu/en/news>

News & Press Releases

No new digest content identified.

.....

.....

India

National Centre for Disease Control

Directorate General of Health Services, Ministry of Health & Family Welfare

Announcements

No new digest content identified.

.....

.....

.....

U.S. Immunization and Public Health Governance/Policy/Funding

Given the continuing extraordinary situation in the U.S., we have established a separate section of the digest to capture and organize key content. Please note that we will selectively include external analysis and comment, indenting this content under the relevant organization/action. We recognize that despite the volume of content in this section, this summary is indicative and not exhaustive.

White House, HHS, FDA, CDC+

White House

Presidential Actions – Executive Orders; Memoranda; Proclamations

No new digest content identified.

Department of State

Press Releases - Selected

No new digest content identified.

HHS

Press Room - Selected

No new digest content identified.

NIH

<http://www.nih.gov/>

News Releases - Selected

No new digest content identified.

FDA

Press Announcements - Selected

FDA Moves to Accelerate Biosimilar Development and Lower Drug Costs

WASHINGTON— OCTOBER 29, 2025 — The U.S. Food and Drug Administration (FDA) today announced significant action to make it faster and less costly to develop biosimilar medicines, which are lower-cost “generic” alternatives to biologic drugs that treat serious and chronic diseases.

In a new [draft guidance](#), the FDA proposes major updates to simplify biosimilarity studies and reduce unnecessary clinical testing. The agency through a separate initiative also plans to make it easier for

biosimilars to be developed as interchangeable with brand-name biologics, helping patients and pharmacists choose lower-cost options more easily.

Expensive biologic medications make up only 5% of prescriptions in the U.S. but account for 51% of total drug spending as of 2024. FDA-approved biosimilars are as safe and effective as the branded drugs, yet their market share remains below 20%. To date, FDA has approved 76 biosimilars, corresponding to a small fraction of approved biologics. By contrast, there are more than 30,000 approved generics, exceeding the number of approved brand drugs. Only about 10% of biologic drugs expected to lose patent protection in the next decade currently have a biosimilar in development...

FDA CBER

Latest News

Scientific Considerations in Demonstrating Biosimilarity to a Reference Product: Updated Recommendations for Assessing the Need for Comparative Efficacy Studies

Draft Guidance for Industry, OCTOBER 2025

FDA VRBPAC [Vaccines and Related Biological Products Advisory Committee]

Advisory Committee Calendar

No future meetings posted.

FDA Pediatric Advisory Committee Meeting

Advisory Committee Calendar

Pediatric Advisory Committee (PAC); Notice of Meeting; Establishment of a Public Docket; Request for Comments

A Notice by the Food and Drug Administration on 10/02/2025

DATES: The meeting will be held on virtually on **November 13, 2025**, from 10:00 a.m. to 4:00 p.m.

Eastern Time (ET). **Comments: November 5, 2025**

CDC

<http://www.cdc.gov/media/index.html>

Latest News - Selected

No new digest content identified.

CDC – Immunization Safety Office (ISO)

<https://www.cdc.gov/vaccine-safety-systems/about/cdc-monitoring-program.html>

No new digest content identified.

ACIP

2026 Meetings Schedule

- February 25-26
- June 24-25
- October 21-22

MMWR Weekly

<https://www.cdc.gov/mmwr/index2025.html>

September 25, 2025 / No. 36

No new edition identified.

National Vaccine Program Committee (NVAC)

<https://www.hhs.gov/vaccines/about/index.html>

Upcoming Meetings/Latest Updates

No 2025 meeting dates posted.

Advisory Commission on Childhood Vaccines (ACCV)

<https://www.hrsa.gov/advisory-committees/vaccines/meetings>

Next ACCV Meeting – TBD [To be re-scheduled from original date January 29, 2025]

.....

NSF

News

No new digest content identified.

.....

U.S. Congress

House of Representatives

No new digest content identified.

U.S. Senate

Senate Health, Education, Labor, and Pensions (HELP) Committee

No new digest content identified.

.....

Supreme Court, Federal & Appellate Courts

No new digest content identified.

.....

.....

U.S. States

No new digest content identified.

.....

.....

.....

U.S. Medical Societies, Health Organizations

American Academy of Pediatrics (AAP)

<https://www.aap.org/en/news-room/news-releases-from-the-aap/>

(Accessed 04 Sep 2025)

News

No new digest content identified.

American College of Physicians (ACP)

<https://www.acponline.org/more-acp-news>

(Accessed 04 Sep 2025)

ACP News

[New Long COVID Resource Hub features evidence-based tools and education](#)

10/28/25

ACP, in collaboration with the Council of Medical Specialty Societies, launched the hub to help clinicians navigate evolving evidence and care for patients experiencing post-COVID-19 conditions
[May require ACP membership for access]

Infectious Diseases Society of America (IDSA)

<https://www.idsociety.org/>

(Accessed 04 Sep 2025)

News releases and statements

No new digest content identified.

American Public Health Association (APHA)

[https://www.apha.org/news-and-media/news-](https://www.apha.org/news-and-media/news-releases?sortFieldName=ItemDate&sortDisplayName=Newest&sortMode=desc)

[releases?sortFieldName=ItemDate&sortDisplayName=Newest&sortMode=desc](https://www.apha.org/news-and-media/news-releases?sortFieldName=ItemDate&sortDisplayName=Newest&sortMode=desc)

(Accessed 04 Sep 2025)

News Releases

No new digest content identified.

Society for Maternal-Fetal Medicine (SMFM)

<https://www.smfm.org/>

(Accessed 04 Sep 2025)

News

No new digest content identified.

Massachusetts Public Health Alliance (MPHA)

<https://mapublichealth.org/press-room/>

(Accessed 04 Sep 2025)

Press Room

No new digest content identified.

American Medical Association (AMA)

<https://www.ama-assn.org/press-center>

(Accessed 04 Sep 2025)

Press Center - Latest News

[AMA urges vaccination in advance of respiratory virus season](#)

Oct 30, 2025

CHICAGO – Ahead of respiratory virus season, the American Medical Association (AMA) encourages everyone to stay up to date with their vaccinations to help lower the risk of severe illness from respiratory viruses.

The AMA recommends everyone 6 months and older—except in rare cases—get an annual flu vaccine. With colder weather driving more people indoors, flu and other respiratory viruses can spread rapidly. October is an ideal time to get vaccinated because it allows the body time to build immunity before respiratory viruses begin spreading widely in the community.

“Last year’s flu season was one of the worst in the U.S. in 15 years, and the statistics speak volumes. Fewer than half of all Americans received a flu vaccine last year, resulting in more than 620,000 hospitalizations and 27,000 deaths related to flu illness,” said AMA President Bobby Mukkamala, MD. “We cannot afford to repeat this pattern. We strongly urge everyone 6 months and older to get a flu vaccine as soon as possible, ideally before the end of October, to protect themselves, their loved ones, and their communities from severe complications, hospitalization, and death.”

Vaccination continues to be the best defense against respiratory viruses and their potentially serious complications. In addition to flu, other respiratory viruses are expected to circulate again this year, including respiratory syncytial virus (RSV) and SARS-CoV-2.

The AMA encourages all adults age 75 and older to get vaccinated against RSV, as well as adults ages 50–74 with certain medical conditions who are at increased risk for severe RSV. The RSV vaccine is not an annual vaccine, so those who have already received an RSV vaccine do

not need another dose. Families also should familiarize themselves with the options to protect infants during RSV season, including vaccination during pregnancy or an RSV monoclonal antibody for infants and young children. Most infants will not need both options.

Anyone 6 months and older who wants a COVID-19 vaccine should be able to get one. Certain populations are at increased risk of severe outcomes from COVID-19 including adults age 65 and older, those with underlying medical conditions, patients who are pregnant, and children 6 to 23 months of age. **The AMA encourages everyone to speak with their physician or other health care professional to determine which vaccines are best for them.**

Taking health precautions, such as covering coughs and sneezes, frequent handwashing, improving indoor air quality, and staying home if you are sick, can also help reduce the spread of flu and other respiratory viruses.

The AMA remains committed to supporting evidence-based immunizations that prevent severe disease and protect public health. The AMA also continues its work to promote public understanding and confidence in vaccines to avoid the resurgence of vaccine-preventable illnesses and deaths.

American Academy of Family Physicians (AAFP)

<https://www.aafp.org/news/media-center.html>

(Accessed 04 Sep 2025)

Statements, Releases

No new digest content identified.

American Geriatrics Society (AGS)

<https://www.americangeriatrics.org/media-center>

(Accessed 04 Sep 2025)

Recent Press Releases

No new digest content identified.

American Osteopathic Association (AOA)

<https://osteopathic.org/news/>

(Accessed 04 Sep 2025)

Latest News

No new digest content identified.

National Medical Association (NMA)

<https://nmanet.org/blog/>

(Accessed 04 Sep 2025)

Latest News

No new digest content identified.

National Foundation for Infectious Diseases (NFID)

<https://www.nfid.org/news-updates/>

(Accessed 04 Sep 2025)

News and Updates

No new digest content identified.

.....
.....

Civil Society – Individuals, Organizations, Institutions



Kaiser Family Foundation/KFF [01 Nov 2025]
https://www.kff.org/search/?post_type=press-release
Newsroom

Global COVID-19 Tracker

Oct 29, 2025 *Issue Brief*

This tracker provides data on global COVID-19 cases and deaths by country, region, and income-level. Additionally, the tracker reports current closure, economic, and health system policy responses to the COVID-19 pandemic globally. This tracker will be updated as new data are available.

Global Disease Outbreaks: A 2025 Snapshot and Implications for the U.S.

Oct 29, 2025 *Issue Brief*

A snapshot of disease outbreaks, with human transmission, which have occurred globally thus far in 2025, using multiple official sources.

...To better understand the current outbreak landscape around the world, and because there is no single database of all global outbreaks, we analyzed data from multiple official sources to develop a snapshot of the number, type, and location of disease outbreaks, with human transmission, which have occurred thus far in 2025. Based on this analysis, we identified more than 100 outbreaks, including some that have affected multiple countries and impacted large populations.

This finding is broadly similar to an estimate from a prior study of the 1996-2023 period that identified an average of 108 outbreaks that occurred each year. However, given that 2025 is not yet over, there could be more outbreaks in the weeks and months ahead. Our finding is also likely an underestimate due to delays in reporting and other factors (see methods for more information).

Findings

Our analysis finds that thus far in 2025 (see Table 1):

- **We identified 102 reported disease outbreaks with human transmission in 66 countries as of October 10, 2025;** this is likely an undercount due to delays in reporting, the multiplicity of outbreaks that may be captured in this analysis as a single outbreak (e.g., the United States has identified 44 distinct outbreaks of measles as of Oct. 7 this year), and other factors.
- **These outbreaks are due to 20 different infectious diseases spanning a wide variety of disease types** (including respiratory, vector-borne, food or waterborne, and direct contact infections) and including avian influenza (H5N1), Chikungunya, cholera, Ebola, Marburg, measles, mpox, Nipah, Rift Valley fever, yellow fever, and Zika, among others.
- **There is significant geographic variation in the occurrence of outbreaks by region.** The greatest number of reported outbreaks have been in sub-Saharan Africa (33 countries), followed by the Western Hemisphere (15), East Asia and the Pacific (7), South and Central Asia (6), and the Near East (Middle East and North Africa, 5).
- **A third of these countries (23) countries have experienced more than one outbreak this year, often of varying scales.** For example, the Democratic Republic of the Congo has reported outbreaks of anthrax, cholera, cVDPV1, Ebola virus disease, mpox, and one outbreak due to an unexplained cause but described now as “acute febrile illness,” and the United States has reported outbreaks of dengue – which is not endemic in the continental U.S. but has caused localized transmission from travel-related imported cases – and measles, which had long been considered eliminated in the U.S., a status that is now at risk due to increasing cases.
- **Outbreaks have ranged in size,** as measured by number of cases as well as the number of affected countries. For example, a single case of Chapare hemorrhagic fever constituted an outbreak in Bolivia, while the largest this year has been the cholera outbreak across 34 countries, which has approached a half million cases and been declared a health emergency by the World Health Organization.
- **Similarly, the number of deaths resulting from these outbreaks has also varied widely, as some virulent infectious diseases have led to high mortality,** such as deaths among all

suspected cases of Marburg virus disease (10 of 10) and deaths among two-thirds of suspected cases of Ebola virus disease (43 of 64). Others have resulted in few deaths but spread rapidly and can have important health impacts, such as chikungunya and mpox.

.....

Vaccine Integrity Project – CIDRAP

<https://www.cidrap.umn.edu/vaccine-integrity-project>

CIDRAP Op-Ed: Vaccine effectiveness and safety: What the numbers truly mean in 2025

Jake Scott, MD

October 31, 2025

This week, our systematic review of COVID-19, respiratory syncytial virus (RSV), and influenza immunizations was published in the *New England Journal of Medicine*. We analyzed 511 studies to provide evidence-based guidance for the upcoming 2025-26 respiratory virus season, work that feels especially urgent as federal vaccine advisory processes face unprecedented disruption.

Clinicians, public health officials, and patients need independent evidence synthesis more than ever. Our review provides extensive data on both the effectiveness and safety for protection against all three respiratory viruses, though interpreting these numbers requires understanding the distinct context surrounding each...

New England Journal of Medicine

Special Article

Updated Evidence for Covid-19, RSV, and Influenza Vaccines for 2025–2026

Authors: Jake Scott, M.D., Michael S. Abers, M.D., Harleen K. Marwah, M.D., Nicole C. McCann, B.A., Eric A. Meyerowitz, M.D., Aaron Richterman, M.D., M.P.H. <https://orcid.org/0000-0001-7920-7191>, Derek F. Fleming, Ph.D., +18, and Caitlin M. Dugdale, M.D.

Published October 29, 2025 DOI: 10.1056/NEJMs2514268

Abstract

Background

Changes in the vaccine advisory process in the United States have disrupted immunization guidance, which reinforces the need for independent evidence review to inform decisions regarding immunization for respiratory viruses during the 2025–2026 season.

Methods

We conducted a systematic review of U.S.-licensed immunizations against coronavirus disease 2019 (Covid-19), respiratory syncytial virus (RSV), and influenza. We searched databases on PubMed/MEDLINE, Embase, and Web of Science for updates of the most recent review by the Advisory Committee on Immunization Practices (ACIP) Evidence-to-Recommendations for each disease, which was performed during the 2023–2024 period. Outcomes included vaccine efficacy and effectiveness against hospitalization, other clinical end points, and safety.

Results

Of 17,263 identified references, 511 studies met the inclusion criteria. Covid-19 mRNA vaccines against the XBB.1.5 subvariant had pooled vaccine effectiveness against hospitalization of 46% (95% confidence interval [CI], 34 to 55; from cohort studies) and 50% (95% CI, 43 to 57; from case-control studies) among adults and 37% (95% CI, 29 to 44) among immunocompromised adults. In a case-control study, vaccines against the KP.2 subvariant showed an effectiveness of 68% (95% CI, 42 to 82). Maternal RSV vaccination (for infant protection), nirsevimab for infants, and RSV vaccines in adults who were 60 years of age or older showed vaccine effectiveness of 68% or more against hospitalization. Influenza vaccination had a pooled vaccine effectiveness of 48% (95% CI, 39 to 55) in adults between the ages of 18 and 64 years and 67% (95% CI, 58 to 75) in children against hospitalization. Safety profiles were consistent

with previous evaluations. The diagnosis of myocarditis associated with Covid-19 vaccines occurred at rates of 1.3 to 3.1 per 100,000 doses in male adolescents, with lower risk associated with longer dosing intervals. The RSVpreF vaccine was associated with 18.2 excess cases of Guillain–Barré syndrome per million doses in older adults; a significant association with preterm birth was not observed when the vaccine was administered at 32 to 36 weeks’ gestation.

Conclusions

Ongoing peer-reviewed evidence supports the safety and effectiveness of immunizations against Covid-19, RSV, and influenza during the 2025–2026 season. (Funded by the Center for Infectious Disease Research and Policy and the Alumbra Innovations Foundation.)

[Excerpt]

... Recent changes to federal vaccine-advisory processes have disrupted immunization guidance, which underscores the need for independent evidence assessment. This systematic review synthesizes recent data regarding respiratory virus epidemiology, vaccine and immunization efficacy and effectiveness, and safety. These data build on the frameworks of the Advisory Committee on Immunization Practices (ACIP) Evidence-to-Recommendations for 2023–2024 to provide clinicians, medical societies, public health professionals, insurers, and policymakers with timely evidence for the 2025–2026 respiratory virus season....

.....
.....

Contents [click to move among sections]

:: [*Milestones, Perspectives*](#)

:: [*WHO*](#)

:: [*Organization Announcements*](#)

:: [*Journal Watch*](#)

:: [*Pre-Print Servers*](#)

.....
.....

Organization Announcements

Paul G. Allen Frontiers Group [01 Nov 2025]

<https://alleninstitute.org/news-press/>

News

[How age affects vaccine responses and how to make them better](#)

Oct 29, 2025

Age-related shifts in T cells weaken vaccine response in older adults, but new findings pave the way for next generation of vaccines.

BMGF - Gates Foundation [01 Nov 2025]

<https://www.gatesfoundation.org/ideas/media-center>

Press Releases & Statements

No new digest content identified.

CARB-X [01 Nov 2025]

<https://carb-x.org/>

News

10.30.2025 |

CARB-X APPOINTS DR. RICHARD ALM AS INTERIM CHIEF OF RESEARCH AND DEVELOPMENT

(Boston: October 30, 2025) – Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) today announced that Richard Alm, Ph.D., will be appointed as Interim Chief of Research & Development (R&D). Dr. Alm joined CARB-X more than six years ago and has served as Chief Scientific Officer since July 2021...

Chan Zuckerberg Initiative [01 Nov 2025]

<https://chanzuckerberg.com/newsroom/>

Newsroom

No new digest content identified.

CEPI – Coalition for Epidemic Preparedness Innovations [01 Nov 2025]

<http://cepi.net/>

CEPI News, Blog

News

Global vaccine safety network to launch in six countries across three continents

28 Oct 2025

News

Establishing the world's largest Nipah virus vaccine reserve

27 Oct 2025

CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 01 Nov 2025]

<https://cioms.ch/>

News; Publications; Events

No new digest content identified.

DARPA – Defense Advanced Research Projects Agency [U.S.] [01 Nov 2025]

<https://www.darpa.mil/news>

News

No new digest content identified.

DNDI – Drugs for Neglected Diseases initiative [01 Nov 2025]

<https://dndi.org/press/press-releases/>

Press Releases

No new digest content identified.

Duke Global Health Innovation Center [01 Nov 2025]

<https://dukeghic.org/>

News

Analysis of Health Budget Practices in 8 Latin American countries: Current Practices, Systemic Challenges, and the Road Ahead for Argentina, Brazil, Chile, Colombia, Costa Rica, Ecuador, Mexico, and Peru

October 30, 2025

Our report, funded by FIFARMA, analyzes how health resources are planned, prioritized, allocated, and managed in eight Latin American countries: Argentina, Brazil, Chile, Colombia, Costa Ric...

Introducing The ALIGN Consortium

October 29, 2025

New Initiative Introducing The ALIGN Consortium Advancing Country-Led Innovation Introduction through Government Engagement and EvidNce The ALIGN Consortium aims to improve health o...

EDCTP [01 Nov 2025]

<http://www.edctp.org/>

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

News

31 October 2025

Free access to the SPIRIT Electronic Protocol Tool and Resource (SEPTRE) platform

30 October 2025

CAP012 SAMBA project: African innovation driving the future of HIV prevention

28 October 2025

Portable molecular testing brings life-saving TB diagnosis closer to communities in sub-Saharan Africa

Emory Vaccine Center [01 Nov 2025]

<http://www.vaccines.emory.edu/>

Vaccine Center News

No new digest content identified.

European Vaccine Initiative [01 Nov 2025]

<http://www.euvaccine.eu/>

News

No new digest content identified.

Fondation Merieux [01 Nov 2025]

<http://www.fondation-merieux.org/>

Actualités

No new digest content identified.

Gates Medical Research Institute [01 Nov 2025]

<https://www.gatesmri.org/news>

The Gates Medical Research Institute is a non-profit organization dedicated to the discovery, development and effective use of novel biomedical interventions addressing substantial global health concerns, for which investment incentives are limited.

News: Articles and Publications

No new digest content identified.

Gavi [to 01 Nov 2025]

<https://www.gavi.org/>

News Releases

27 October 2025

[Gavi, WHO, and UNICEF strengthen commitment to cervical cancer prevention in Mozambique, protecting nearly 3 million girls](#)

27 October 2025

[Zambia launches malaria vaccine to protect over half million children](#)

GE2P2 Global Foundation [01 Nov 2025]

www.ge2p2.org

News/Analysis/Publications-Digests/Statements

Digests

:: [Vaccines and Global Health: The Week in Review - Current edition](#)

:: [Informed Consent: A Monthly Review – May 2025](#)

:: [Public Consultations Watch :: Global Calls for Input/Public Comment – 03 Oct 2025](#)

:: [Genomics :: Governance, Ethics, Policy, Practice – A Monthly Digest – May 2025](#)

GHIT Fund [01 Nov 2025]

<https://www.ghitfund.org/newsroom/press>

Press Releases

October 29, 2025

[Total Investment of Approx. USD 11.6 Million in TB and NTD R&D projects with Partners including FUJIFILM, Stop TB Partnership, and the Ohio State University](#)

Global Fund [to 01 Nov 2025]

<https://www.theglobalfund.org/en/news/>

News Releases

No new digest content identified.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [01 Nov 2025]

<https://www.glopid-r.org/>

News & Events

No new digest content identified.

Hilleman Laboratories [01 Nov 2025]

<http://www.hilleman-labs.org/>

News & Insights

No new digest content identified.

HHMI - Howard Hughes Medical Institute [01 Nov 2025]

<https://www.hhmi.org/news>

Press Room

No new digest content identified.

Human Immunome Project [nee Human Vaccines Project] [01 Nov 2025]

<https://www.humanimmunomeproject.org/>

News

No new digest content identified.

IAVI [01 Nov 2025]

<https://www.iavi.org/>

Press Releases, Features

Features

[IAVI calls for innovative partnerships to sustain vaccine development at the World Vaccine Congress Europe 2025](#)

October 30, 2025

IAVI's experts underscored the value of equitable, regional partnerships in bringing new vaccines to market at this year's convening in Amsterdam

INSERM [01 Nov 2025]

<https://www.inserm.fr/en/home/>

Press Releases

No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]

<http://www.icmra.info/drupal/en/news>

Selected Statements, Press Releases, Research

29 October 2025

[Appointment of new ICMRA Chair](#)

The Chair of the International Coalition of Medicines Regulatory Authorities (ICMRA) is Professor Anthony (Tony) Lawler. He began his mandate as ICMRA Chair on 23 October 2025.

29 October 2025

[PQKM ICMRA-industry virtual workshop - materials and video recording](#)

CMRA-industry virtual workshop: Strengthening regulatory convergence and reliance through Pharmaceutical Quality Knowledge Management

ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use] [to 01 Nov 2025]

<https://www.ich.org/>

News/Pubs/Press Releases [Selected]

[ICH: E20 EWG Adaptive Designs for Clinical Trials](#)

ICH Public consultation dates:

ANMAT, Argentina - Deadline for comments by 8 October 2025
EC, Europe - Deadline for comments by 30 November 2025
Health Canada, Canada - Deadline for comments by 25 September 2025
MHRA, UK - Deadline for comments by 30 November 2025
Swissmedic, Switzerland - Deadline for comments by 30 November 2025
TFDA, Chinese Taipei - Deadline for comments by 13 October 2025

USA, FDA, Deadline 12/01 2025 Docket No. FDA-2025-D-3023

The E20 EWG is working on the development of a new E20 Guideline on "Adaptive Clinical Trials" on the design, conduct, analysis, and interpretation of adaptive clinical trials that provides a transparent and harmonized set of principles for the regulatory review of these studies in a global drug development program. These principles should also provide the flexibility to evaluate / discuss innovative approaches to clinical trial design throughout the development process.

Rapporteur: Dr. Gregory Levin (FDA, United States)

Regulatory Chair: Dr. Christian Roes (EC, Europe)

Date of Step 2b: 25 June 2025 Status: Step 3

Ongoing Public Consultations	^
> M4Q(R2) EWG Revision of M4Q(R1)	
> Q3E EWG Guideline for Extractables and Leachables	
> E20 EWG Adaptive Designs for Clinical Trials	

<https://www.ich.org/page/public-consultations>

ICRC [to 01 Nov 2025]

<https://www.icrc.org/en/news>

News

Global military leaders gather in Riyadh as ICRC President opens landmark workshop on the Laws of War

News release 01-11-2025

ICRC president: World leaders must act to end the indiscriminate killing in Sudan

News release 31-10-2025

Sudan: ICRC Statement on the Situation in Darfur

Statement 29-10-2025

IFFIm [01 Nov 2025]

<http://www.iffim.org/>

Press Releases/Announcements

No new digest content identified.

IFRC [to 01 Nov 2025]

<http://media.ifrc.org/ifrc/news/press-releases/>

Press releases

Press release 31/10/2025

Cuba: IFRC launches emergency appeal to assist 100,000 people affected by Hurricane Melissa while arbovirus outbreak risk rises

Press release 30/10/2025

Jamaica: IFRC launches emergency appeal in response to Hurricane Melissa. Aid distribution is well under way

IPPS - International Pandemic Preparedness Secretariat [01 Nov 2025]

<https://ippsecretariat.org/news/>

News

No new digest content identified.

Institut Pasteur [01 Nov 2025]

<https://www.pasteur.fr/en/press-area>

Press Documents

No new digest content identified.

ISC / International Science Council [to 01 Nov 2025]

<https://council.science/current/>

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

news

30 October 2025 - 8 min read

10 new insights in climate science

Land carbon sinks cannot keep up, while rising temperatures spread disease and threaten incomes – warns a new report by FutureEarth, the World Climate Research Programme and the Earth League.

statements

28 October 2025 - 10 min read

ISC position on research funding transparency

The International Science Council (ISC) has released a new position calling for the fully transparent disclosure of all research funding sources to be recognized as a shared responsibility and adopted as a core norm by all levels of the global science system.

PDF: <https://council.science/wp-content/uploads/2025/10/International-Science-Council-statement-on-research-funding-transparency.pdf>

The ISC holds that universal research funding transparency is a crucial part of responsible scientific practice and the first line of defense against the compromise of research integrity and the spread of misinformation and disinformation. The ISC recommends that:

1. All levels of the global science system adopt the norm, where legal, of explicitly disclosing the extent of financial and other support provided by funders to researchers and that this be noted in all public communications by the researcher such as articles, websites, presentations, conferences and in all contexts where the researcher can reasonably be taken to be speaking as an expert.
2. All scientific journals require formal declarations of the source of funding for research which they publish.
3. The obligation to disclose research funding be recognized as shared between universities, learned societies, unions, funding bodies and other scientific organizations, and not held to be the sole responsibility of individual researchers.
4. Institutions and organizations be proactive in developing mechanisms to ensure routine and standardized research funding transparency.

International Union of Immunological Societies (IUIS)

<https://iuis.org/>

News, Resources

[IUIS 2025 Congress Recordings Now Available on ImmunoHub](#)

September 30, 2025

IVAC [01 Nov 2025]


<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

Updates; Events

U.S. Measles Tracker

[Tracking Measles Cases in the U.S.](#)

Updated October 31, 2025



IVI [01 Nov 2025]

<http://www.ivi.int/>

IVI News & Announcements

[IVI and Bloom Public Health Group partner to advance vaccine equity and strengthen health security in Africa](#)

29 October 2025 — The International Vaccine Institute (IVI) and Bloom Public Health Group announced a new partnership to accelerate vaccine equity and strengthen health security across Africa.

A memorandum of understanding formalizes the collaboration, leveraging IVI's global scientific expertise and Bloom's on-the-ground knowledge to build a more resilient African vaccine ecosystem.

Johns Hopkins Center for Health Security [01 Nov 2025]

<https://centerforhealthsecurity.org/newsroom>

Center News [Selected]

No new digest content identified.

Robert Wood Johnson Foundation [to 01 Nov 2025]

<https://www.rwjf.org/en/about-rwjf/newsroom.html>

Latest News and Highlights

[Statement From Richard Besser, MD, on the Expiration of SNAP, WIC, and ACA Benefits](#)

Statement Oct-31-2025

MSF/Médecins Sans Frontières [to 01 Nov 2025]

<http://www.msf.org/>

Latest [Selected Announcements]

Conflict in Sudan

[Urgent appeal for El Fasher's people - MSF denounces mass atrocities and fears many people remain in grave d...](#)

Press Release 31 Oct 2025

Democratic Republic of Congo

[MSF hands over Ebola response activities in DRC](#)

Press Release 31 Oct 2025

South Sudan

[South Sudan's cholera crisis is a symptom of deeper failures](#)

Op-Ed 28 Oct 2025

National Academy of Medicine - USA [to 01 Nov 2025]

<https://nam.edu/programs/>

News, Stories, Insights

No new digest content identified.

National Academies-Sciences-Engineering-Medicine [NASEM]- USA [to 01 Nov 2025]

<https://www.nationalacademies.org/newsroom>

News

No new digest content identified.

PATH [01 Nov 2025]

<https://www.path.org/media-center/>

Newsroom [Selected]

[PATH joins WHO's Global Clinical Trials Forum](#)

October 23, 2025 by PATH

PATH has joined the World Health Organization's (WHO's) newly launched Global Clinical Trials Forum (GCTF), a global, multi-stakeholder network designed to strengthen clinical trial environments and infrastructure at national, regional, and global levels.

The network connects diverse stakeholders—including Member States, regulators, ethics authorities, funders, researchers, civil society, and patient and community engagement organizations—and provides a collaborative platform for members to share guidance, knowledge, and best practices that can help strengthen capacity and advance inclusive, ethical, and impactful clinical trials...

Sabin Vaccine Institute [01 Nov 2025]

<https://www.sabin.org/press/>

Latest News & Press Releases

No new digest content identified.

UNAIDS [01 Nov 2025]

<http://www.unaids.org/en>

News, Stories, Updates

No new digest content identified.

UNICEF [to 01 Nov 2025]

<https://www.unicef.org/media/press-releases>

Latest press releases, news notes and statements [Selected]

Press release 30 October 2025

Over 700,000 children affected after Hurricane Melissa slams the Caribbean

PANAMA CITY, 30 October 2025 -, Several days of torrential rains, storm surges and catastrophic flooding caused by Hurricane Melissa have impacted the lives of more than 700,000 children across the Caribbean, according to UNICEF estimates. The strong storm that directly hit Jamaica and Cuba and affected the Carib...

News note 29 October 2025

No child safe in Al Fasher

NEW YORK, 29 October 2025, -, UNICEF is gravely concerned by the images and reports coming from Al Fasher, in the Darfur region of Sudan. The escalating violence has left thousands of children, already besieged for more than 500 days, further trapped amid relentless shelling, heavy fighting, and severe shortages of food, safe water, and medicine. "No child is safe," said...

Press release 26 October 2025

At least 1.6 million children at risk as Hurricane Melissa moves through the Caribbean

PANAMA CITY, 26 October 2025 -, As Hurricane Melissa is moving slowly across the Caribbean Sea, , the winds, torrential rains, and flash flooding have put at least 1.6 million children at risk, ,, according to UNICEF estimates. Caribbean countries, including Jamaica, Haiti, Cuba, and the Dominican Republic, ar...

Unitaid [01 Nov 2025]

<https://unitaid.org/>

Press Releases

No new digest content identified.

Vaccine Equity Cooperative [nee Initiative] [01 Nov 2025]

<https://vaccineequitycooperative.org/news/>

News

No new digest content identified.

Vaccine Confidence Project [01 Nov 2025]

<http://www.vaccineconfidence.org/>

News, Research and Reports

No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia [01 Nov 2025]

<http://www.chop.edu/centers-programs/vaccine-education-center>

News

October 2025 – Hepatitis B Vaccine Birth Dose and Separating MMR

Check out two videos in which Dr. Paul Offit discusses vaccines in the news: hepatitis B vaccine birth dose and separating MMR vaccine into individual components.

Wellcome Trust [01 Nov 2025]

<https://wellcome.org/news/all>

News. Opinion, Reports

Researcher story

Hope in the hotspots – how local research is turning the tide against cholera

30 October 2025

Despite being treatable, cholera deaths have doubled over the last year. Wellcome-funded researchers in Kenya are uncovering how simple interventions and mapping hotspots can prevent outbreaks.

The Wistar Institute [to 01 Nov 2025]

<https://www.wistar.org/news/press-releases>

Press Releases

October 30, 2025

The Wistar Institute Appoints Two New Members to its Board of Trustees

The Wistar Institute, a global leader in biomedical research in cancer, immunology and infectious disease, is pleased to welcome David Krupnick and Elliot Menschik, M.D., Ph.D., to its Board of Trust...

World Bank [to 01 Nov 2025]

<http://www.worldbank.org/en/news/all>

News [Selected]

World Bank Group Statement on Support for Jamaica

Our thoughts are with the people of Jamaica as they face the devastating impact of Hurricane Melissa. We are working closely with the Government of Jamaica and international partners, including the Inter-American...

Date: October 31, 2025 Type: Statement

Increasing Regional Collaboration to Strengthen Health Systems across Central Africa

Unlocking employment opportunities through regional investments that strengthen health security and promote inclusive job creation WASHINGTON, October 29, 2025 - The World Bank Board of Directors...

Date: October 30, 2025 Type: Press Release Language: English

WFPHA: World Federation of Public Health Associations [01 Nov 2025]

<https://www.wfpfa.org/>

Blog, Events

No new digest content identified.

World Medical Association [WMA] [to 06 Sep 025]

<https://www.wma.net/news-press/press-releases/>

Press Releases

World Medical Association Strongly Condemns the Massacre of Patients and Health Workers in Sudan

31st October 2025

World Organisation for Animal Health [OIE] [01 Nov 2025]

<https://www.oie.int/>

Press Releases, Statements

Press Release

World Organisation for Animal Health hosts biothreat conference to address high stakes of global health security

27 October 2025, Paris – Amid growing concern over a fragile and conflict-prone world, the World Organisation for Animal Health (WOAH) will host a landmark global gathering to advance inclusive dialogue and the formation of transformative alliances for a more secure, healthier future.

The Global Conference on Biological Threat Reduction will take place on 28-30 October 2025 in Geneva, Switzerland. Bringing together experts from a variety of fields, the event will offer a platform to discuss rising security risks and strategies to bridge the biological threat reduction gap...

.....

.....

ARM [Alliance for Regenerative Medicine] [01 Nov 2025]

<https://alliancerm.org/press-releases/>

Selected Press Releases

No new digest announcements identified.

BIO [01 Nov 2025]

<https://www.bio.org/press-releases>

Press Releases

No new digest announcements identified.

DCVMN – Developing Country Vaccine Manufacturers Network [01 Nov 2025]

<http://www.dcvmn.org/>

News; Upcoming events

No new digest announcements identified.

ICBA – International Council of Biotechnology Associations [01 Nov 2025]

<https://internationalbiotech.org/news/>

News

No new digest announcements identified.

IFPMA [01 Nov 2025]

<https://ifpma.org/>

Statement 30 Oct 2025

75th WHO Regional Committee for Europe on the Action Plan for the Prevention and Control of Noncommunicable Diseases in the WHO European Region 2016–2025

On 30 October 2025 at the 75th WHO Regional Committee for Europe, IFPMA, together with European member association EFPIA, submitted a statement on the Action Plan for the Prevention and Control of Noncommunicable Diseases in the WHO European Region 2016-2025. This statement is delivered on behalf of IFPMA and its European member organization EFPIA. We...

Position paper 27 October 2025

Policy considerations for the development, regulation and adoption of biosimilars

International Alliance of Patients' Organizations – IAPO [01 Nov 2025]

<https://www.iapo.org.uk/news>

Press and media [Selected]

No new digest announcements identified.

International Generic and Biosimilar Medicines Association [IGBA]

<https://www.igbamedicines.org/>

News

No new digest announcements identified.

PhRMA [01 Nov 2025]

<http://www.phrma.org/>

Press Releases

No new digest announcements identified.

.....
.....

Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements

We recognize that this listing is indicative but certainly not exhaustive. We invite nomination of other vaccine developers for potential addition to those monitored below.

AstraZeneca

Press Releases - No new digest announcements identified.

Bavarian Nordic

Latest News

Bavarian Nordic Provides Further Support to Mpox Outbreak in Africa through Additional Donation of Vaccines

COPENHAGEN, Denmark, October 28, 2025 – Bavarian Nordic announced today a donation of mpox vaccines to Africa CDC to support the response to the ongoing mpox outbreak in Africa.

The donation of 110,000 doses of the vaccine has been allocated to Uganda in coordination with the key partners involved in the mpox Access and Allocation Mechanism (AAM), significantly increasing the availability of vaccines in the country, which has reported the second-highest number of cases of mpox in Africa in 2025. The vaccines were delivered to Uganda earlier this week.

Paul Chaplin, President & CEO of Bavarian Nordic, said: "Mpox remains a health emergency in Africa as evidenced by the continued spread across the continent and increase in number of cases. The continued availability of funding and vaccines is critical for a successful public health response, and we are pleased to reinforce our commitment through another donation of our mpox vaccine."...

BioCubaFarma – Cuba

Últimas Noticias - No new digest announcements identified.

Biological E

News - No new digest announcements identified.

BioNTech

Press Releases - No new digest announcements identified.

Boehringer

Press Releases - No new digest announcements identified.

CanSinoBIO

News - Website not responding at inquiry.

CIGB

Latest News - No new digest announcements identified.

CinnaGen

Recent News - No new digest announcements identified.

Clover Biopharmaceuticals – China

News - No new digest announcements identified.

CSL Seqirus

News Releases - No new digest announcements identified.

Curevac

News - No new digest announcements identified.

Dailchi Sankyo

Press Releases - No new digest announcements identified.

Gamaleya National Center/Sputnik

Latest News and Events - No new digest announcements identified [Last: 09 Nov 2020]

<https://sputnikvaccine.com/> - No new digest announcements identified [Last: 31 Aug 2022]

GSK

Press releases for media

29 October 2025

[GSK delivers strong Q3 performance and upgrades 2025 guidance](#)

Specialty Medicines, Vaccines and General Medicines drive sales, profit and earnings growth

...Vaccines sales £2.7 billion (+2%); Shingrix £0.8 billion (+13%); Meningitis vaccines £0.5 billion (+5%); and Arexvy £0.3 billion (+36%)

EuBiologics, S Korea

News - No new digest announcements identified.

HIPRA

Press releases - No new digest announcements identified.

IMBCAMS, China

Home - Website not responding at inquiry.

JNJ Innovative Medicine [Janssen]

Press Releases - No new digest announcements identified.

Merck

News releases - No new digest announcements identified.

Nanogen

News - No new digest announcements identified.

Novartis

News - No new digest announcements identified.

Novavax

Press Releases - No new digest announcements identified.

Pfizer

Recent Press Releases - No new digest announcements identified.

R-Pharm

<https://rpharm-us.com/index.php>

[No news or media page identified]

Sanofi Pasteur

Press Releases - No new digest announcements identified.

Serum Institute

News & Announcements

Establishing the world's largest Nipah virus vaccine reserve

:: CEPI, Serum Institute of India Pvt Ltd. and the University of Oxford collaborate to manufacture ChAdOx1 NipahB vaccines for Phase II trials and investigational ready reserve of up to 100,000 doses.

:: Reserve doses could be deployed under emergency use during a future Nipah virus outbreak, helping generate critical data and potentially halt an epidemic in its tracks.

:: Advancing clinical testing and manufacturing of a Nipah vaccine will strengthen regional defences against the disease.

28 October 2025

Sinopharm/WIBPBIBP

News - No new digest announcements identified.

Sinovac

Press Releases - No new digest announcements identified.

SK Biosciences

Press Releases

SK bioscience strengthens global vaccine partnerships to expand R&D pipeline competitiveness

:: Hilleman Laboratories holds its Board meeting in Korea to deepen collaboration with SK bioscience

:: Visit to SK bioscience headquarters and R&D center highlights joint commitment to global vaccine innovation

:: Partnerships with global health organizations including the Gates Foundation, CEPI, and IVI continue to expand

2025.10.29

Takeda

Newsroom - No new digest announcements identified.

Valneva

Press Releases - No new digest announcements identified.

WestVac Biopharma

Media - No new digest announcements identified.

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

Website [No News/Announcements page identified]

.....
.....

Contents [click to move among sections]

:: Milestones, Perspectives

:: WHO

:: Organization Announcements

:: Journal Watch

:: Pre-Print Servers

.....
.....

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 16, 2025 Issue 3

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

AMA Journal of Ethics

Volume 27, Number 10: E713-767 Oct 2025

<https://journalofethics.ama-assn.org/issue/diagnostic-research>

Diagnostic Research

What exactly is a medical mystery? Any one condition of illness could be diagnosed, misdiagnosed, a missed diagnosis, undiagnosed, or perhaps something else. The National Institutes of Health (NIH) defines undiagnosed diseases as "long-standing symptoms or elusive medical conditions that have not been diagnosed despite extensive clinical evaluation." What is now known as the Undiagnosed Diseases Network (UDN) was a research study first established by the NIH in 2008 and is now funded by the National Institute of Neurological Disorders and Stroke. Its charge is to convene experts, conduct research on human subjects at 14 US clinic locations, forge new knowledge, and "solve the most challenging medical mysteries." UDN research subjects must apply with supporting documentation from their clinicians and health records. Fewer than half of UDN applicants are enrolled in a protocol, and, among subjects evaluated by clinician-investigators, some receive a diagnosis. This theme issue considers a range of neglected diagnostic research ethics questions and investigates ethics questions about UDN policies, practices, and public support.

American Journal of Human Genetics

Oct 02, 2025 Volume 112 Issue 10 p2251-2562

<https://www.cell.com/ajhg/current>

This month in The Journal

Paul W. Hook, Alyson B. Barnes

Obesity and obesity-related traits have a major impact on global health. While a myriad of genes and variants have been associated with these traits, substantial functional work still needs to be performed to understand the underlying molecular mechanisms. In this issue, Baya et al. identify genes associated with obesity and fat distribution using exome sequencing from the UK Biobank and test their function in a human adipocyte cell line. Using rare variant gene burden tests, the authors find 69 genes associated with traits, including body mass index (BMI), waist-to-hip ratio adjusted for BMI, and body fat percentage.

[Reviewed earlier]

American Journal of Infection Control

November 2025 Volume 53 Issue 11 p1131-1242

<http://www.ajicjournal.org/current>

[New issue; No digest content identified]

American Journal of Preventive Medicine

November 2025 Volume 69 Issue 5

<https://www.ajpmonline.org/current>

Research Articles

Pediatric Vaccine Limiting Through Age 23 Months Among U.S. Military Families

Celeste J. Romano, Monica T. Burrell, Clinton Hall,...Gia R. Gumbs, Ava Marie S. Conlin, Nanda Ramchandar

Published online: July 31, 2025

108012

American Journal of Public Health

November 2025 115(11)

<http://ajph.aphapublications.org/toc/ajph/current>

[New issue; No digest content identified]

American Journal of Tropical Medicine and Hygiene

Volume 113 (2025): Issue 4 (Oct 2025)

<https://www.ajtmh.org/view/journals/tpmd/113/3/tpmd.113.issue-4.xml>

[New issue; No digest content identified]

Annals of Internal Medicine

October 2025 Volume 178, Issue 10

<https://www.acpjournals.org/toc/aim/current>

[Reviewed earlier]

Artificial Intelligence – An International Journal

Volume 347 October 2025

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/346/suppl/C>

[Reviewed earlier]

BMC Cost Effectiveness and Resource Allocation

<http://resource-allocation.biomedcentral.com/>

(Accessed 01 Nov 2025)

[No new digest content identified]

BMC Health Services Research

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 01 Nov 2025)

[No new digest content identified]

BMC Infectious Diseases

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 01 Nov 2025)

[No new digest content identified]

BMC Medical Ethics

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 01 Nov 2025)

[Operationalizing AI ethics in medicine—a co-creation workshop study](#)

A majority of AI ethics frameworks focus on high-level principles but lack actionable guidance. Effectively implementing AI in projects requires the operationalization of AI ethics, translating principles into...

Authors: Luis M. Lopez-Ramos, Gabriele Pluktaite, Cathrine K. T. Bui, Julia Amann, Tamarinde Haven and Vince I. Madai

Citation: *BMC Medical Ethics* 2025 26:150
Content type: Research Published on: 29 October 2025

BMC Medicine

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 01 Nov 2025)

[No new digest content identified]

BMC Pregnancy and Childbirth

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 01 Nov 2025)

No new digest content identified]

BMC Public Health

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 01 Nov 2025)

No new digest content identified]

BMC Research Notes

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 01 Nov 2025)

[No new digest content identified]

BMJ Evidence-Based Medicine

October 2025 - Volume 30 - 5

<https://ebm.bmj.com/content/30/5>

[Reviewed earlier]

BMJ Global Health

October 2025 - Volume 10 - 10

<https://gh.bmj.com/content/10/10>

[Reviewed earlier]

Bulletin of the Atomic Scientists

DIGITAL MAGAZINE - September 2025

<https://thebulletin.org/magazine/2025-09/#post-heading>

[Reviewed earlier]

Bulletin of the World Health Organization

Volume 103, Number 10, October 2025, 577-640

<https://www.who.int/publications/journals/bulletin/>

[Reviewed earlier]

Cell

Oct 02, 2025 Volume 188 Issue 20 p5433-5784

<https://www.cell.com/cell/current>

[Reviewed earlier]

Cell and Gene Therapy Insights

May 2025 Issue Volume 11 Issue 4

<https://www.insights.bio/cell-and-gene-therapy-insights/journal/250/volume-11-issue-4>

[Reviewed earlier]

Child Care, Health and Development

Volume 51, Issue 6 November 2025

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

Clinical Pharmacology & Therapeutics

Volume 118, Issue 4 Pages: 749-966 October 2025

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

[Reviewed earlier]

Clinical Therapeutics

October 2025 Volume 47 Issue 10 p827-956

<http://www.clinicaltherapeutics.com/current>

[Reviewed earlier]

Clinical Trials

Volume 22 Issue 5, October 2025

<https://journals.sagepub.com/toc/ctja/22/5>

[Reviewed earlier]

Conflict and Health

<http://www.conflictandhealth.com/>

[Accessed 01 Nov 2025]

[No new digest content identified]

Contemporary Clinical Trials

Volume 157 October 2025

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/157/suppl/C>

[Reviewed earlier]

The CRISPR Journal

Volume 8, Issue 5 / October 2025

<https://www.liebertpub.com/toc/crispr/8/5>

[Reviewed earlier]

Current Genetic Medicine Reports

Volume 13, Issue 1 December 2025

<https://link.springer.com/journal/40142/volumes-and-issues/13-1>

[Reviewed earlier]

Current Medical Research and Opinion

Volume 41, Issue 3 2025

<https://www.tandfonline.com/toc/icmo20/current>

[Reviewed earlier]

Current Opinion in Infectious Diseases

October 2025 - Volume 38 - Issue 5

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

PAEDIATRIC AND NEONATAL INFECTIONS

[Reviewed earlier]

Current Protocols in Human Genetics

<https://currentprotocols.onlinelibrary.wiley.com/journal/19348258>

[Accessed 01 Nov 2025]

[No new digest content identified]

Cytotherapy

October 2025 Volume 27 Issue 10 p1151-1270

<https://www.isct-cytotherapy.org/current>

[Reviewed earlier]

Developing World Bioethics

Volume 25, Issue 3 Pages: 165-252 September 2025

<https://onlinelibrary.wiley.com/toc/14718847/current>

[Reviewed earlier]

Development in Practice

Volume 35, Issue 5, 2025

<https://www.tandfonline.com/toc/cdip20/35/5?nav=tocList>

[Reviewed earlier]

Development Policy Review

Volume 43, Issue 5 September 2025

<https://www.tandfonline.com/toc/cdip20/35/5?nav=tocList>

[Reviewed earlier]

Disaster Medicine and Public Health Preparedness

Volume 19 - 2025

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

Disasters

Volume 49, Issue 4 October 2025

<https://onlinelibrary.wiley.com/toc/14677717/current>

Future of humanitarian and development aid

[Reviewed earlier]

eBioMedicine

Volume 120 October 2025

<https://www.sciencedirect.com/journal/ebiomedicine/vol/120/suppl/C>

[New issue; No digest content identified]

EMBO Reports

Volume 26 Issue 198 October 2025

<https://www.embopress.org/toc/14693178/current>

[Reviewed earlier]

Emerging Infectious Diseases

Volume 31, Number 10—October 2025

<http://wwwnc.cdc.gov/eid/>

[New issue; No digest content identified]

Epidemics

Volume 52 September 2025

<https://www.sciencedirect.com/journal/epidemics/vol/52/suppl/C>

[Reviewed earlier]

Epidemiology and Infection

Volume 153 - 2025

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

Ethics & Human Research

Volume 47, Issue 5 Pages: 1-43 September–October 2025

<https://onlinelibrary.wiley.com/toc/25782363/current>

[Reviewed earlier]

Ethics & International Affairs

Volume 39 - Issue 2 - Summer 2025

<https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue> [

Roundtable: Global Governance in Hard Times

[Reviewed earlier]

Ethics, Medicine and Public Health

Volume 32 2024

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/32/suppl/Cc>

[Reviewed earlier]

The European Journal of Public Health

Volume 35, Issue 4, August 2025

<https://academic.oup.com/eurpub/issue/35/4>

[Reviewed earlier]

Expert Review of Vaccines

Volume 24, 2025 Issue 1

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

Foreign Affairs

November/December 2025 Volume 104, Number 6

<https://www.foreignaffairs.com/issues/2025/104/5>

[Reviewed earlier]

Forum for Development Studies

Volume 52, 2025 - Issue 2

<http://www.tandfonline.com/toc/sfds20/current>

The Rebirth of the Global South: Geopolitics, Imageries, and Developmental Realities

[Reviewed earlier]

Frontiers in Genetics

<https://www.frontiersin.org/journals/genetics>

[Accessed 01 Nov 2025]

[No new digest content identified]

Frontiers in Genome Editing

<https://www.frontiersin.org/journals/genome-editing>

[Accessed 01 Nov 2025]

[No new digest content identified]

Frontiers in Medicine

<https://www.frontiersin.org/journals/medicine/volumes?volume-id=1463>

[Accessed 01 Nov 2025]

[No new digest content identified]

Gene Therapy – Nature

Volume 32 Issue 5, October 2025

<https://www.nature.com/gt/volumes/32/issues/5>

[Reviewed earlier]

Genetics in Medicines

Volume 27, Issue 6 June 2025

<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/27/issue/65>

[Reviewed earlier]

Genome Medicine

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 01 Nov 2025]

[No new digest content identified]

Global Health Action

Volume 18, Issue 1 (2025)

<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>

[Reviewed earlier]

Global Health: Science and Practice (GHSP)

August 2025 | Volume 13 | Number 1

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

Global Legal Monitor & Legal Reports – Library of Congress/USA

<https://www.loc.gov/collections/global-legal-monitor/>

https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc

[Accessed 01 Nov 2025]

[No new digest content identified]

Global Public Health

Volume 20, Issue 1 (2025)

<http://www.tandfonline.com/toc/rqph20/current>

[Reviewed earlier]

Globalization and Health

<http://www.globalizationandhealth.com/>

[Accessed 01 Nov 2025]

[No new digest content identified]

Health and Human Rights

Volume 27, Issue 1, June 2025

<https://www.hhrjournal.org/volume-27-issue-1-june-2025/>

SPECIAL SECTION - FIGHT FOR RIGHTS VIEWPOINT SERIES

[Reviewed earlier]

Health Economics, Policy and Law

Volume 20 - Issue 4 - October 2025

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>
Article

[Safety of scientific medical research is a State obligation](#)

Marjolein Timmers, Mária Éva Földes

Published online by Cambridge University Press:

13 May 2025, pp. 368-380

Health Policy and Planning

Volume 40, Issue 8, September 2025

<https://academic.oup.com/heapol/issue/40/8>

[Reviewed earlier]

Health Research Policy and Systems

<http://www.health-policy-systems.com/content>

[Accessed 01 Nov 2025]

[No new digest content identified]

Human Gene Therapy

Volume 36, Issue 17-18 / September 2025

<https://www.liebertpub.com/toc/hum/36/17-18>

[Reviewed earlier]

Humanitarian Practice Network

<https://odihpn.org/>

[Accessed 01 Nov 2025]

Featured Publications

[No new digest content identified]

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 21 Issue 1, 2025

<https://www.tandfonline.com/toc/khvi20/21/1?nav=tocList>

Selected Content

[Reviewed earlier]

Immunity

Sep 09, 2025 Volume 58 Issue 9 p2139-2354

<https://www.cell.com/immunity/current>

[Reviewed earlier]

Infectious Agents and Cancer

<http://www.infectagentscancer.com/>

[Accessed 01 Nov 2025]

[No new digest content identified]

Infectious Diseases of Poverty

<http://www.idpjournals.com/content/>

[Accessed 01 Nov 2025]

[No new digest content identified]

International Health

Volume 17, Issue 5, September 2025

<https://academic.oup.com/inthealth/issue/17/5>

[Reviewed earlier]

International Human Rights Law Review

Volume 14 (2025): Issue 1 (Jun 2025)

<https://brill.com/view/journals/hrlr/14/1/hrlr.14.issue-1.xml>

[Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol. 12 No. 9 (2025): September 2025

<https://www.ijcmph.com/index.php/ijcmph/issue/view/128>

[Reviewed earlier]

International Journal of Epidemiology

Volume 54, Issue 3, June 2025

<https://academic.oup.com/ije/issue/54/3>

[Reviewed earlier]

International Journal of Human Rights in Healthcare

Volume 18, Issue 3 4 September 2025

<https://www.emerald.com/ijhrh/issue/18/3>

Table of contents

[Reviewed earlier]

JAMA

October 28, 2025, Vol 334, No. 16, Pages 1409-1494

<https://jamanetwork.com/journals/jama/currentissue>

Original Investigation

[Bivalent RSV Prefusion F Protein–Based Vaccine for Preventing Cardiovascular Hospitalizations in Older Adults](#)
[A Prespecified Analysis of the DAN-RSV Trial](#)

Mats C. Højbjerg Lassen, MD; Niklas Dyrby Johansen, MD, PhD; Sine H. Christensen, MSc; et al.

has active quiz has audio

JAMA. 2025;334(16):1431-1441. doi:10.1001/jama.2025.15405

This prespecified secondary outcome analysis of a randomized clinical trial assesses the effect of a bivalent respiratory syncytial virus (RSV) prefusion F protein–based vaccine on incidence of hospitalization for cardiorespiratory disease among adults aged 60 years or older.

- [Podcast](#): From ESC: Remote Monitoring for Atrial Fibrillation, Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction, and more

Editorial

[Shot Through the Heart—Can RSV Vaccination Reduce Risk of Cardiovascular Outcomes?](#)

Helen Y. Chu, MD, MPH; Alastair F. Murray, MD

[RSV Vaccine Effectiveness Against Hospitalization Among US Adults Aged 60 Years or Older During 2 Seasons](#)

Diya Surie, MD; Wesley H. Self, MD, MPH; Katharine A. Yuengling, MPH; et al.

JAMA. 2025;334(16):1442-1451. doi:10.1001/jama.2025.15896

This study investigates respiratory syncytial virus vaccine effectiveness against hospitalization among US adults aged 60 years or older during 2 seasons.

Research Letter

[Respiratory Syncytial Virus Vaccination in Adult Allogeneic Hematopoietic Cell Transplant Recipients](#)

Jonas Lötscher, MD, PhD; Carla Simone Walti, MD; Stefanie Heller; et al.

JAMA. 2025;334(16):1478-1480. doi:10.1001/jama.2025.16744

This study examines the humoral and cell-mediated immune responses among allogeneic hematopoietic cell transplant recipients following vaccination with prefusion F glycoprotein-based vaccines.

JAMA Health Forum

October 2025, Vol 6, No. 10

<https://jamanetwork.com/journals/jama-health-forum/issue>

[Reviewed earlier]

JAMA Pediatrics

October 2025, Vol 179, No. 10, Pages 1051-1136

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[Reviewed earlier]

JBIR Evidence Synthesis

October 2025 - Volume 23 - Issue 10

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Adolescent Health

October 2025 Volume 77 Issue 4 p587-796

<https://www.jahonline.org/current>

[Reviewed earlier]

Journal of Artificial Intelligence Research

Vol. 83 (2025)

<https://www.jair.org/index.php/jair>

[Reviewed earlier]

Journal of Bioethical Inquiry

Volume 22, Issue 1 March 2025

<https://link.springer.com/journal/11673/volumes-and-issues/22-1>

[Reviewed earlier]

Journal of Community Health

Volume 50, Issue 5 October 2025

<https://link.springer.com/journal/10900/volumes-and-issues/50-5>

Articles

[Reviewed earlier]

Journal of Current Medical Research and Opinion

...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.

Vol. 8 No. 01 (2025)

<https://www.cmro.in/index.php/jcmro/issue/view/91>

[Reviewed earlier]

Journal of Development Economics

Volume 176 September 2025

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/176/suppl/C>

[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics

Volume 20 Issue 4, October 2025

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

Journal of Epidemiology & Community Health

September 2025 - Volume 79 - 9

<https://jech.bmj.com/content/79/9>

[Reviewed earlier]

Journal of Evidence-Based Medicine

Volume 18, Issue 3 September 2025

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

Journal of Global Ethics

Volume 21, Issue 2 (2025)

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 36, Number 3, August 2025

<https://muse.jhu.edu/issue/55342>

Table of Contents

[Reviewed earlier]

Journal of Immigrant and Minority Health

Volume 27, Issue 4 August 2025

<https://link.springer.com/journal/10903/volumes-and-issues/27-4>

[Reviewed earlier]

Journal of Immigrant & Refugee Studies

Volume 23, Issue 3 (2025)

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

Journal of International Development

Volume 37, Issue 7 Pages: 1-1567 October 2025

<https://onlinelibrary.wiley.com/toc/10991328/current>

[Reviewed earlier]

Journal of Law, Medicine & Ethics

Volume 53 - Issue 3 - Fall 2025

<https://www.cambridge.org/core/journals/journal-of-law-medicine-and-ethics/latest-issue>

Public Health, Markets, and Law

[Reviewed earlier]

Journal of Medical Ethics

October 2025 - Volume 51 - 10

<http://jme.bmj.com/content/current>

[Reviewed earlier]

Journal of Patient-Centered Research and Reviews

Volume 12, Issue 3 (2025)

<https://institutionalrepository.aah.org/jpcrr/>

[Reviewed earlier]

The Journal of Pediatrics

Volume 284 September 2025

<https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/284/suppl/C>
[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice

Volume 18, 2025 Issue 1

<https://www.tandfonline.com/toc/jppp20/18/1?nav=tocList>

[Reviewed earlier]

Journal of Public Health Management & Practice

September/October 2025 - Volume 31 - Issue 5

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Public Health Policy

Volume 46, Issue 3 September 2025

<https://link.springer.com/journal/41271/volumes-and-issues/46-3>

[Reviewed earlier]

Journal of the Royal Society – Interface

October 2025 Volume 22 Issue 231

<https://royalsocietypublishing.org/toc/rsif/current>

[Reviewed earlier]

Journal of Travel Medicine

Volume 32, Issue 6, August 2025

<https://academic.oup.com/jtm/issue>

[Reviewed earlier]

Journal of Virology

Volume 99 • Number 6 • June 2025

<http://jvi.asm.org/content/current>

[Reviewed earlier]

The Lancet

Nov 01, 2025 Volume 406 Number 10515 p2033-2190

<https://www.thelancet.com/journals/lancet/issue/current>

[New issue; No digest content identified]

The Lancet Child & Adolescent Health

Oct 2025 Volume 9 Number 10 p685-752

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

Lancet Digital Health

Sep 2025 Volume 7 Number 9

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

Lancet Global Health

Oct 2025 Volume 13 Number 10 e1654-e1780

<https://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

Lancet Infectious Diseases

Nov 2025 Volume 25 Number 11 p1159-1264, e621-e675

<https://www.thelancet.com/journals/laninf/issue/current>

Editorial

The promise of lifelong vaccination

The Lancet Infectious Diseases

[Excerpts]

... As populations age globally, however, adult vaccination is emerging as a crucial tool for ensuring healthy ageing and resilient health systems—both through disease prevention and cost savings from averted care. Adult vaccination can also promote antimicrobial stewardship by directly reducing the incidence of antimicrobial-resistant infections and indirectly reducing antibiotic use. A recent [WHO technical report](#) estimated that licensed vaccines could reduce antibiotic use by 142 million defined daily doses annually if coverage was expanded, in turn reducing annual hospital costs associated with antimicrobial-resistant infections. In a [2024 report](#) on the socioeconomic value of adult immunisation programmes, the Office of Health Economics found that benefit–cost analyses of adult vaccination programmes against seasonal influenza, pneumococcal disease, herpes zoster, and respiratory syncytial virus in ten high-income and upper-middle-income countries (once again, scarce data are available for low-income countries) showed returns of up to 19 times initial investment.

Given these cost benefits and the large number of diverse vaccines in development (such as vaccines against Lyme borreliosis [eg, [NCT05477524](#)] and Epstein-Barr virus [eg, [NCT06908096](#)]), new vaccination strategies are needed to improve vaccine access and scale up delivery to adults...

The success of initiatives aimed at improving adult vaccine uptake and delivery will probably determine the sustainability of global health systems more generally. This success will require collaboration among governments and industries and clear communication about health-care services and the quality of life that people deserve at all ages.

Articles

Effectiveness and impact of nirsevimab in Chile during the first season of a national immunisation strategy against RSV (NIRSE-CL): a retrospective observational study

Juan Pablo Torres, et al.

Lancet Public Health

Oct 2025 Volume 10 Number 10 e804-e88

<https://www.thelancet.com/journals/lanpub/issue/current>

[Reviewed earlier]

Lancet Respiratory Medicine

Oct 2025 Volume 13 Number 10 p857-950, e53-e55

<https://www.thelancet.com/journals/lanres/issue/current>
[New issue; No digest content identified]

Maternal and Child Health Journal

Volume 29, Issue 10 October 2025

<https://link.springer.com/journal/10995/volumes-and-issues/29-10>
[Reviewed earlier]

Medical Decision Making (MDM)

Volume 45 Issue 7, October 2025

<http://mdm.sagepub.com/content/current>
[Reviewed earlier]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy

Volume 103, Issue 3 Pages: 639-939 September 2025

<https://onlinelibrary.wiley.com/toc/14680009/current>
[Reviewed earlier]

Molecular Therapy

Oct 01, 2025 Volume 33 Issue 10 p4657-5282

<https://www.cell.com/molecular-therapy/current>

In this issue

The advent of mRNA vaccines has revolutionized vaccine development, offering a swift and versatile development platform. One advantage possessed by mRNA vaccines is the ability to express antigens in soluble/secreted forms or transmembrane (TM) forms, which can better mimic the native viral envelope (Env) protein. Previous research has indicated some improvements in immune responses with the use of a TM Env trimer immunogen over the use of a secreted antigen, but the picture of the impact of TM antigens on the full immune response has remained incomplete.

Nature

Volume 646 Issue 8087, 30 October 2025

<https://www.nature.com/nature/volumes/646/issues/8087>
[New issue; No digest content identified]

Nature Biotechnology

Volume 43 Issue 10, October 2025

<https://www.nature.com/nbt/volumes/43/issues/10>
[Reviewed earlier]

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 01 Nov 2025)

[Reviewed earlier]

Nature Genetics

Volume 57 Issue 10, October 2025

<https://www.nature.com/ng/volumes/57/issues/10>

[Reviewed earlier]

Nature Human Behaviour

Volume 9 Issue 10, October 2025

<https://www.nature.com/nathumbehav/volumes/9/issues/10>

[New issue; No digest content identified]

Nature Medicine

Volume 31 Issue 10, October 2025

<https://www.nature.com/nm/volumes/31/issues/10>

[Reviewed earlier]

Nature Reviews Drug Discovery

Volume 24 Issue 10, October 2025

<https://www.nature.com/nrd/volumes/24/issues/10>

[Reviewed earlier]

Nature Reviews Genetics

Volume 26 Issue 10, October 2025

<https://www.nature.com/nrg/volumes/26/issues/10>

[Reviewed earlier]

Nature Reviews Immunology

Volume 25 Issue 10, October 2025

<https://www.nature.com/nri/volumes/25/issues/1>

[Reviewed earlier]

New England Journal of Medicine Volume

Volume 393 No. 17 October 30, 2025

<https://www.nejm.org/toc/nejm/medical-journal>

[New issue; No digest content identified]

NEJM Evidence

Volume 4 No. 9 September 2025

<https://evidence.nejm.org/toc/evid/current>

NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.

[Reviewed earlier]

njp Vaccines

<https://www.nature.com/npjvaccines/>

[Accessed 01 Nov 2025]
[No new digest content identified]

Pediatrics

Volume 156, Issue 4 October 2025
<https://publications.aap.org/pediatrics/issue/156/3>
[Reviewed earlier]

PharmacoEconomics

Volume 43, Issue 10 October 2025
<https://link.springer.com/journal/40273/volumes-and-issues/43-10>
[Reviewed earlier]

PLoS Biology

<https://journals.plos.org/plosbiology/>
(Accessed 01 Nov 2025)
[No new digest content identified]

PLoS Genetics

<https://journals.plos.org/plosgenetics/>
(Accessed 01 Nov 2025)
[No new digest content identified]

PLoS Global Public Health

https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60
(Accessed 01 Nov 2025)

[Strengthening vaccine effectiveness research to rebuild public trust: A call for global participation](#)

Giorgia Sulis, Melissa Brouwers
Opinion | published 29 Oct 2025 PLOS Global Public Health
<https://doi.org/10.1371/journal.pgph.0005359>

PLoS Medicine

<https://journals.plos.org/plosmedicine/>
(Accessed 01 Nov 2025)
[No new digest content identified]

PLoS Neglected Tropical Diseases

<http://www.plosntds.org/>
(Accessed 01 Nov 2025)
[No new digest content identified]

PLoS One

<http://www.plosone.org/>
[Accessed 01 Nov 2025]
[No new digest content identified]

PLoS Pathogens

<http://journals.plos.org/plospathogens/>
[Accessed 01 Nov 2025]
[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States Current Issue

October 28, 2025 vol. 122 no. 43
<https://www.pnas.org/toc/pnas/122/43>
[New issue; No digest content identified]

PNAS Nexus

Volume 4, Issue 9, September 2025
<https://academic.oup.com/pnasnexus/issue/4/9>
[Reviewed earlier]

Prehospital & Disaster Medicine

Volume 40 - Issue 3 - June 2025
<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>
[Reviewed earlier]

Preventive Medicine

Volume 198 September 2025
<https://www.sciencedirect.com/journal/preventive-medicine/vol/198/suppl/C>
[Reviewed earlier]

Proceedings of the Royal Society B

October 2025 Volume 292 Issue 2056
<https://royalsocietypublishing.org/toc/rspb/current>
[Reviewed earlier]

Public Health

Volume 246 September 2025
<https://www.sciencedirect.com/journal/public-health/vol/246/suppl/C>
[Reviewed earlier]

Public Health Ethics

Volume 18, Issue 2, July 2025
<http://phe.oxfordjournals.org/content/current>
[Reviewed earlier]

Public Health Genomics

2025, Vol. 28, No. 1

<https://karger.com/phg/issue/28/1>

[Reviewed earlier]

Public Health Reports

Volume 140 Issue 4, July/August 2025

<https://journals.sagepub.com/toc/phrg/140/4>

[Reviewed earlier]

Qualitative Health Research

Volume 35 Issue 12, October 2025

<https://journals.sagepub.com/toc/QHR/current>

[Reviewed earlier]

Research Ethics

Volume 21 Issue 4, October 2025

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

Reproductive Health

<http://www.reproductive-health-journal.com/content>

[Accessed 01 Nov 2025]

[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

<https://www.paho.org/journal/en>

Latest Articles

[No new digest content identified]

Risk Analysis

Volume 45, Issue 10 Pages: 2927-3330 October 2025

<https://onlinelibrary.wiley.com/toc/15396924/current>

[Reviewed earlier]

Risk Management and Healthcare Policy

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 01 Nov 2025]

[No new digest content identified]

Royal Society Open Science

October 2025 Volume 12 Issue 10
<https://royalsocietypublishing.org/toc/rsos/current>
[Reviewed earlier]

Science

Volume 45, Issue 10 Pages: 2927-33 30 October 2025

<https://www.science.org/toc/science/current>

Research Articles

Collateral effects of COVID-19 pandemic control on the US infectious disease landscape

BY Tobias S. Brett, Pejman Rohani

30 Oct 2025:

Editor's summary

The massive range and costs of interventions undertaken to limit the harms caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had many side effects. Using surveillance data from the Centers for Disease Control and Prevention for notifiable infectious diseases, Brett and Rohani made a comprehensive statistical analysis of the indirect impact of the pandemic on a range of infections occurring in the US (see the Perspective by Durrheim). Although several endemic infections have rebounded to prepandemic levels of notification since 2020, the overall burden from infectious disease has been reduced. —Caroline Ash

Abstract

Using data from the United States Centers for Disease Control and Prevention (CDC) disease surveillance systems, we sought to quantify the indirect effects of the COVID-19 pandemic, and the possibility of lack of exposure to common pathogens resulting in immune deficits. Clustering analysis on pandemic-era time-series data identified pathogen groupings according to transmission mechanism. Counterfactual analysis, using Bayesian structural time-series (BSTS) modeling, confirmed that infectious diseases that are directly transmitted via airborne droplets (aerosols) experienced the greatest disruption to transmission. By contrast, sexually transmitted infections (STIs) experienced a smaller transient disruption, and increasing trends in incidence prepandemic appear to have been curtailed. Using epidemiological theory, we demonstrate that the observed magnitudes and durations of notifications deficits were determined by fundamental disease system properties, namely, the serial interval, basic reproductive number, and susceptible recruitment.

Science and Engineering Ethics

Volume 31, Issue 5 October 2025

<https://link.springer.com/journal/11948/volumes-and-issues/31-5>

[Reviewed earlier]

Science Translational Medicine

Volume 17| Issue 822| 29 Oct 2025

<https://www.science.org/toc/stm/current>

[New issue; No digest content identified]

Scientific Reports

<https://www.nature.com/srep/articles?type=article>

[Accessed 01 Nov 2025]

[No new digest content identified]

Social Science & Medicine

Volume 380 September 2025

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/380/suppl/C>

[Reviewed earlier]

Systematic Reviews

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 01 Nov 2025]

[No new digest content identified]

Theoretical Medicine and Bioethics

Volume 46, Issue 5 October 2025

<https://link.springer.com/journal/11017/volumes-and-issues/46-5>

[Reviewed earlier]

Travel Medicine and Infectious Diseases

Volume 67 September–October 2025

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/67/suppl/C>

[Reviewed earlier]

Tropical Medicine & International Health

Volume 30, Issue 10 Pages: 1025-1143 October 2025

<https://onlinelibrary.wiley.com/toc/13653156/current>

[Reviewed earlier]

Vaccine

Volume 66 14 November 2025

<https://www.sciencedirect.com/journal/vaccine/vol/66/suppl/C>

Short communication Open access

[**Advancing typhoid conjugate vaccine implementation in Asia: Regional policy priorities**](#)

Alice S. Carter, Duncan Steele, Jacob John, Senjuti Saha, ... Denise O. Garrett

Article 127848

Review article Open access

[**Exploring the effectiveness of interventions to increase uptake of measles vaccination among healthcare workers: a systematic review**](#)

Nikki Heinze, Alex F. Martin, Anna S.C. Tirion, Riinu Pae, ... G. James Rubin

Article 127808

Review article Abstract only

[**Influenza vaccine hesitancy in the elderly: Where do we stand?**](#)

Carla Pires

Article 127831

Review article Abstract only

[**Monitoring strategies after the incorporation of vaccines into national immunization programs: a systematic review**](#)

Ana Catarina de Melo Araújo, Alice Gomes Frugoli, Jéssica Emanuela de Sena Gonçalves, Jadher Pércio, ... Éder Gatti Fernandes
Article 127850

Research article Abstract only

Exploring the predictors for the uptake of Respiratory Syncytial Virus (RSV) vaccine under the immunization programme in India

Rhythm Hora, Arindam Ray, Amrita Kumari, Mili Dutta, ... Arup Deb Roy
Article 127827

Research article Open access

Determinants of parental readiness for childhood vaccination: experiences, information, sociodemographics and adherence

Bo T. Hansen, Ingrid Borlaug Østlie, Margrethe Greve-Isdahl, Rebecca Nybru Gleditsch
Article 127809

Vaccines

<https://www.mdpi.com/journal/vaccines>

[Accessed 01 Nov 2025]

Open Access Article

Nineteen-Year Evidence on Measles–Mumps–Rubella Immunization in Mexico: Programmatic Lessons and Policy Implications

by Rodrigo Romero-Feregrino, Raul Romero-Feregrino, Raul Romero-Cabello, Berenice Muñoz-Cordero, Benjamin Madrigal-Alonso and Valeria Magali Rocha-Rocha

Vaccines 2025, 13(11), 1126; <https://doi.org/10.3390/vaccines13111126> (registering DOI) - 31 Oct 2025

Abstract

Background: In Mexico, the measles vaccine was first introduced in 1971. The last case of measles acquired through endemic transmission was recorded in 1995. In 1998, the monovalent measles vaccine was replaced by the combined measles–mumps–rubella (MMR) vaccine. The MMR vaccination schedule consists [...]

Open Access Article

Eliminating Measles: Factors That Contribute to Re-Establishing Transmission

by Emily Gibson, David N. Durrheim and Patrick O'Connor

Vaccines 2025, 13(11), 1125; <https://doi.org/10.3390/vaccines13111125> (registering DOI) - 31 Oct 2025

Abstract

Background/Objectives: Since 2016, 14 countries previously verified to have eliminated endemic measles transmission have lost their elimination status. To explore whether there were identifiable risk factors for re-establishing measles transmission in these countries, a narrative review of the literature was undertaken. This [...]

Open Access Review

Global Perspectives on HPV Vaccination: Achievements, Challenges, and Lessons from the Brazilian Experience

by Antonio Braga, Caroline Alves de Oliveira Martins, Gabriela Paiva, Érica de Almeida Barboza, Marcela Chagas, Gustavo Yano Callado, Edward Araujo Júnior, Jorge de Rezende-Filho, Isabel Cristina Chulvis do Val Guimarães, Roberta Granese, Gloria Calagna and Susana Cristina Aidé Viviani Fialho

Vaccines 2025, 13(11), 1106; <https://doi.org/10.3390/vaccines13111106> - 29 Oct 2025

Abstract

Background: The introduction of prophylactic HPV vaccination has transformed cervical cancer prevention worldwide, yet many low- and middle-income countries face persistent challenges in implementation, coverage gaps, and vaccine hesitancy. This article presents a narrative review of global and Brazilian HPV vaccination programs, highlighting [..

Value in Health

October 2025 Volume 28 Issue 10 p1461-1600

<https://www.valueinhealthjournal.com/current>

[Reviewed earlier]

World Development

Volume 195 November 2025

<https://www.sciencedirect.com/journal/world-development/vol/195/suppl/C>

[Reviewed earlier]

.....
.....

Contents [click to move among sections]

:: [*Milestones, Perspectives*](#)

:: [*WHO*](#)

:: [*Organization Announcements*](#)

:: [*Journal Watch*](#)

:: [*Pre-Print Servers*](#)

.....
.....

Pre-Print Servers

arxiv

<https://arxiv.org/>

[Accessed 01 Nov 2025]

[Filters: Emerging Technologies; Neural and Evolutionary Computing; Computers and Society; Genomics; Neurons and Cognition; Populations and Evolution; Other Quantitative Biology; General Economics]

arXiv:2510.26525 [pdf, other]

[Biological Engineering: What does it mean? Where does it - need to - go?](#)

Ulrike A. Nuber, Viktor Stein

Comments: 19 pages, 2 Figures, 2 Tables

Biological engineering, the convergence between engineering and biology, is at the forefront of significant advances in healthcare, agriculture, and environmental sustainability, making it highly relevant to current scientific and societal challenges. We take a comprehensive look at this broad and interdisciplinary domain, structure it into three main areas - bioinspired, biological and biohybrid approaches - and dissect inherent and fundamental challenges along with opportunities, highlighting specific examples. We describe how data-driven discovery and design, in conjunction with artificial intelligence, can mitigate the absence of reductionist models in these areas. Additionally, we address the education of a new generation of biological engineers, emphasizing mathematical, technical, and artificial intelligence frameworks.

arXiv:2510.25218 [pdf, other]

Human Resilience in the AI Era -- What Machines Can't Replace

Shaoshan Liu, Anina Schwarzenbach, Yiyu Shi

AI is displacing tasks, mediating high-stakes decisions, and flooding communication with synthetic content, unsettling work, identity, and social trust. We argue that the decisive human countermeasure is resilience. We define resilience across three layers: psychological, including emotion regulation, meaning-making, cognitive flexibility; social, including trust, social capital, coordinated response; organizational, including psychological safety, feedback mechanisms, and graceful degradation. We synthesize early evidence that these capacities buffer individual strain, reduce burnout through social support, and lower silent failure in AI-mediated workflows through team norms and risk-responsive governance. We also show that resilience can be cultivated through training that complements rather than substitutes for structural safeguards. By reframing the AI debate around actionable human resilience, this article offers policymakers, educators, and operators a practical lens to preserve human agency and steer responsible adoption.

Gates Open Research

<https://gatesopenresearch.org/browse/articles>

[Accessed 01 Nov 2025]

[Filter: All articles]

Method Article metrics

Addressing Research Readiness Challenges in African Institutions: Development and Application of a Modular Assessment Tool

Patrick Amboka, H Kariuki, Nosa Orobato, Alphonsus Neba, Julius Kirimi Sindi

Funder Gates Foundation

PUBLISHED 27 Oct 2025

Historically, African research institutions have faced significant barriers to gaining recognition on a global stage due to limited infrastructure, underdeveloped governance frameworks, and low representation in high-impact publications. This underrepresentation reflects systemic barriers such as the lack of visibility of both researchers and institutions, limited funding, inadequate infrastructure, and fragmented institutional arrangements, which impede the continent's ability to contribute robustly to the global knowledge economy. To address these barriers, the Research Readiness Assessment Survey (RRAS) was developed as a modular, context-specific tool to evaluate and enhance institutional research capacity across multiple dimensions, including research infrastructure, policy and policy engagement, governance, human resources, institutional arrangements, grant management, and research outputs.

medRxiv

<https://www.medrxiv.org/content/early/recent>

[Accessed 01 Nov 2025]

[Filter: All articles]

Knowledge, perceptions and acceptance of COVID-19 Vaccine in Plateau State, Nigeria: A Qualitative Study

Sophia Osawe, Sussan Israel-Isah, Timothy Adejoh, Tunde A Alabi, Felicia Okolo, Sikiratu Babamale, Adam Abdullahi, Alash'le Abimiku

medRxiv 2025.10.16.25338166; doi: <https://doi.org/10.1101/2025.10.16.25338166> Revision

Cost-Effectiveness of Infant and Maternal RSV Immunization Strategies, in British Columbia, Canada

Javad Taleshi, Marina Viñeta Paramo, Allison Watts, Mark Chilvers, Jeffrey Man Hay Wong, Jolanta Piszczek, Lea Separovic, Jia Hu, Danuta Skowronski, Pascal M. Lavoie, Hind Sbihi

medRxiv 2025.06.27.25330432; doi: <https://doi.org/10.1101/2025.06.27.25330432> Revision

Measuring the Impact of Global R&D Investment in Product Development Partnerships (PDPs): A Case Study on Return on Investment in Antimalarial Drug Development

Paula Christen, Céline Audibert, Jo-Ann Mulligan, Oliver Bubb-Humfries, Christian von Drehle, Lesong Conteh

medRxiv 2025.06.17.25329737; doi: <https://doi.org/10.1101/2025.06.17.25329737> *Revision*

Assessment of Safety and Acceptance toward Covid-19 Vaccines: A cross-sectional Study in Egypt

Rehab H. Werida, Mohamed T. Amralla, Nader N. Bekhit, Mena Youssef, Gaidaa M. Dogheim

medRxiv 2025.10.28.25338945; doi: <https://doi.org/10.1101/2025.10.28.25338945>

Quantifying the benefits of improved operations for polio outbreak response: A model-based analysis

Yuming Sun, Pinar Keskinocak, Stephanie D. Kovacs, Lauren N. Steimle

medRxiv 2025.10.15.25338096; doi: <https://doi.org/10.1101/2025.10.15.25338096> *Revision*

Barriers to reaching the Zero-Dose and Under Immunized Children in Uganda: a qualitative rapid assessment

Emmanuel Mugisha, Shadiha Nanteza Mugizi, Deogratias Agaba, Jacqueline Anena, Joanita I. Nankabirwa, Susan Nayiga, Carol Kamya, Faith Namugaya, Paul Katamba, Patrick Albert Ipola, Fred Isaasi, Peter Waiswa, Allen Kabagenyi, Miriam Kayendeke, David Wafula, Betty Mirembe, Moses R. Kamya, Mayora Chrispus

medRxiv 2025.10.20.25338036; doi: <https://doi.org/10.1101/2025.10.20.25338036>

Oral rabies vaccine baiting and targeted removal strategies for dog-mediated rabies outbreak control: a modelling framework for outbreak management

Guan Tong, Rayson Bock Hing Lim, Shi Hui Jin, Kelvin Ho, Alwyn Tan, Malcolm Soh, Wendy Sng, A Janhavi, Gregory Gan, Ma Pei, Nigel Lim, Jue Tao Lim, Tze-Hoong Chua, Borame L Dickens

medRxiv 2025.10.26.25338851; doi: <https://doi.org/10.1101/2025.10.26.25338851>

Optimizing the timing of one or two doses of pneumococcal conjugate vaccines in older adults in the United States: a modeling study

Deus Thindwa, Anabelle Wong, Matthieu Domenech de Cellès

medRxiv 2025.10.24.25338736; doi: <https://doi.org/10.1101/2025.10.24.25338736>

OSF Pre-prints

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences>

[Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-prints]

[No new digest content identified]

Wellcome Open Research

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 01 Nov 2025]

Research Article Open Access

Adoption and use of the 7-1-7 timeliness metrics for detection, notification, and early response actions to public health events: an observational study in Liberia, January 2024–June 2025

[version 1; peer review: awaiting peer review]

Ralph W. Jetoh, et al.

Abstract

Background

In July 2021, a new global target of 7-1-7 was proposed to improve early detection, notification and rapid control of public health threats. Liberia adopted 7-1-7 metrics in September 2023, with the framework embedded in the health and data monitoring systems by January 2024. The study aimed to document factors that influenced 7-1-7 adoption and assess how well the health systems performed for 7-1-7 metrics between January 2024 and June 2025.

Methods

This observational study had a cross-sectional design for 7-1-7 adoption using primary data and a cohort design for 7-1-7 performance using secondary data. Five national and 105 subnational staff were interviewed using a semi-structured questionnaire on 7-1-7 adoption, while research assistants extracted 7-1-7 performance data along with recorded bottlenecks and enablers from the 7-1-7 data consolidation spreadsheet.

Results

Key factors in successful adoption of 7-1-7 involved having a 7-1-7 champion, a dedicated coordination team, strong and committed leadership and effective stakeholder engagement at both national and subnational levels. Of 138 public health events, 134 (97%) were recorded against 7-1-7 targets. Mpox constituted 81 (61%) of these events. The median (range) times to detection, notification and completion of early response actions were 6 days (0-69), 0 days (0-6) and 7 days (1-129) respectively. The 7-day detection target was met in 97 (71%) events, the 1-day notification target in 131 (98%) and the 7-day response target in 79 (59%). Overall, 58 (43%) events met all three targets. Key bottlenecks were: inadequately trained health-care workers and poor community engagement for detection; electronic surveillance issues and poor network coverage for notification; and inadequate resources, logistics and delayed laboratory reporting for early response actions. Strong coordination among public health units was a key enabler.

Conclusions

The 7-1-7 metrics are measurable, achievable and highlight performance bottlenecks and enablers for improvement and increased investments.

*

*

*

*

Think Tanks

Brookings [to 01 Nov 2025]

<http://www.brookings.edu/>

Research, Events

No new digest content identified.

Center for Global Development [01 Nov 2025]

<https://www.cgdev.org/>

All Research

WORKING PAPER

[Health Taxes and the IMF: What 15 Years of Policy Advice Reveal](#)

Sanjeev Gupta and Ainhua Petri-Hidalgo

October 27, 2025

Excise taxes on tobacco, alcohol, and sugar-sweetened beverages can both raise revenue and improve health, but they have not been a central focus of IMF policy advice. There's an opportunity for stronger emphasis going forward.

Chatham House [to 01 Nov 2025]
<https://www.chathamhouse.org/>
Selected Analysis, Comment, Events
No new digest content identified.

Council on Foreign Relations [01 Nov 2025]
<https://www.cfr.org/media/news-releases>
New Releases [Selected]
No new digest content identified.

CSIS [01 Nov 2025]
<https://www.csis.org/>
Reports [Selected]
No new digest content identified.

McKinsey Global Institute [01 Nov 2025]
<https://www.mckinsey.com/mgi/overview>
Featured Research
No new digest content identified.

ODI [Overseas Development Institute] [to 01 Nov 2025]
<https://odi.org/en/publications/>
Publications [Selected]
No new digest content identified.

Pew Research Center [01 Nov 2025]
<https://www.pewresearch.org/>
Latest Publications [Selected]
No new digest content identified.

Rand [to 01 Nov 2025]
<https://www.rand.org/pubs.html>
Published Research [Selected]
Research Oct 31, 2025

[Experiential Learning from Rapid Evaluation in Health and Care](#)

We argue that rapid evaluation provides essential evidence into time-sensitive decision-making by planners and policymakers, while requiring an approach that can help balance the inherent trade-off between rapidity and rigour.

Expert Insights Oct 30, 2025

[The Economic Legacy of Magna Carta](#)

This perspective examines the economic legacy of Magna Carta asks whether today's SDG 16 - peace, justice and strong institutions - could have a similarly transformative impact, showing that investment in justice yields clear economic returns.

Commentary Oct 28, 2025

Defining Risk in Biological Research: Why Researchers Need Clearer Oversight Frameworks

As the U.S. government continues to consider the future for dangerous gain-of-function policies, ongoing research and refining objective and reproducible assessment tools can strike the right balance: preventing misuse while still supporting the science that drives innovations in medicine and biotechnology.

Urban Institute [to 01 Nov 2025]

<https://www.urban.org/research>

New Research Publications - Selected

World Economic Forum [to 01 Nov 2025]

<https://agenda.weforum.org/press/>

Media [Selected]

No new digest content identified.

.....
.....

Public Consultations/Call for Inputs/Call for Papers

ICH: E20 EWG Adaptive Designs for Clinical Trials

ICH Public consultation dates:

ANMAT, Argentina - Deadline for comments by 8 October 2025

EC, Europe - Deadline for comments by 30 November 2025

Health Canada, Canada - Deadline for comments by 25 September 2025

MHRA, UK - Deadline for comments by 30 November 2025

Swissmedic, Switzerland - Deadline for comments by 30 November 2025

TFDA, Chinese Taipei - Deadline for comments by 13 October 2025

USA, FDA, Deadline 12/01/2025 Docket No. FDA-2025-D-3023

The E20 EWG is working on the development of a new E20 Guideline on "Adaptive Clinical Trials" on the design, conduct, analysis, and interpretation of adaptive clinical trials that provides a transparent and harmonized set of principles for the regulatory review of these studies in a global drug development program. These principles should also provide the flexibility to evaluate / discuss innovative approaches to clinical trial design throughout the development process.

Rapporteur: Dr. Gregory Levin (FDA, United States)

Regulatory Chair: Dr. Christian Roes (EC, Europe)

Date of Step 2b: 25 June 2025 Status: Step 3

Pediatric Advisory Committee (PAC); Notice of Meeting; Establishment of a Public Docket; Request for Comments

A Notice by the Food and Drug Administration on 10/02/2025 **Comments: November 5, 2025**

DATES: The meeting will be held on virtually on November 13, 2025, from 10:00 a.m. to 4:00 p.m. Eastern Time (ET).

SUMMARY:

The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Pediatric Advisory Committee (PAC). The general function of the Committee is to provide advice and recommendations to FDA on pediatric regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document.

Comments received on or before November 5, 2025, will be provided to the Committee. Comments received after that date will be taken into consideration by FDA. In the event that the meeting is cancelled, FDA will continue to evaluate any relevant applications or information, and consider any comments submitted to the docket, as appropriate.

The docket number is FDA-2025-N-1246. The docket will close on November 12, 2025.

National Institute of Mental Health, Interagency Autism Coordinating Committee Call for Committee Membership Nominations

A Notice by the National Institutes of Health on 09/24/2025 **Nominations due November 10, 2025.**

SUMMARY:

The Office of the Secretary of the Department of Health and Human Services (HHS) is seeking nominations of individuals to serve as non-federal public members on the Interagency Autism Coordinating Committee (IACC).

The Office of National Autism Coordination (ONAC) of the National Institute of Mental Health, National Institutes of Health is assisting the Department in conducting an open nomination process. Appointments of non-federal public members to the committee shall be made by the Secretary of Health and Human Services.

Expedited Programs for Regenerative Medicine Therapies for Serious Conditions; Draft Guidance for Industry; Availability

A Notice by the Food and Drug Administration on 09/25/2025 **Comment period ends 11/24/2025.**

Docket No. FDA-2017-D-6159 :: 21 pages

SUMMARY:

This guidance provides sponsors engaged in the development of regenerative medicine therapies for serious or life-threatening diseases or conditions with our recommendations on the expedited development and review of these therapies, including as provided under section 506(g) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), as added by section 3033 of the 21st Century Cures Act (Cures Act). Under section 506(g) of the FD&C Act, a regenerative medicine therapy can be designated as a regenerative advanced therapy if it meets certain criteria. FDA refers to such designation as "regenerative medicine advanced therapy" (RMAT) designation (see section III.C of this document). This guidance describes the expedited programs available to sponsors of regenerative medicine therapies for serious conditions, including those products designated as RMATs. To that end, the guidance provides information about the provisions in the Cures Act regarding the use of the accelerated approval pathway for regenerative medicine therapies that have been granted designation as an RMAT. Finally, the guidance describes considerations in the clinical development of regenerative medicine therapies and opportunities for sponsors of such products to interact with the Center for Biologics Evaluation and Research (CBER) review staff. As a general matter, this guidance addresses regenerative medicine therapies regulated by CBER as biological products under the FD&C Act, section 351 of the Public Health Service Act (PHS Act) (42 U.S.C. 262), and applicable regulations.

Innovative Designs for Clinical Trials of Cellular and Gene Therapy Products in Small Populations; Draft Guidance for Industry; Availability

A Notice by the Food and Drug Administration on 09/25/2025 **Comment period ends (11/24/2025).**

Malaria: Developing Drugs for Treatment; Draft Guidance for Industry; Availability

A Notice by the Food and Drug Administration on 09/23/2025. **Comment period ends 12/22/2025.** Docket No. FDA-2025-D-0918

* * * *

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

* * * *
* * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy ([CVEP](#)) / GE2P2 Global Foundation, which is solely responsible for its content.

.....

Copyright GE2P2 Global Foundation 2025. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

.....

CVEP is a program of the [GE2P2 Global Foundation](#) whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the [Bill & Melinda Gates Foundation](#) and industry resource members Janssen/J&J, Pfizer, Sanofi US, and GSK. (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

* * * *
* * * *